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ABSTRACT 
 
Flavonoids are a group of plant secondary metabolites that are vital to the cell systems of 
plants. The intake of these chemicals is advantageous to animals for their antioxidant properties 
that affect the function of immune and inflammatory cells. The bitter taste of grapefruit (Citrus 
paradisi) and other citrus species is caused by the accumulation of glycosylated flavonoids. 
Glucosyltransferases (GTs) are enzymes that add glucose moieties to a carbon or hydroxyl group 
of natural products.  The function of a putative secondary product GT clone was tested.  In 
previous research, putative GT 4 was cloned into a pCD1 modified pET expression system, 
heterologously expressed in E.coli, and screened for activity with a few substrates; little GT 
activity was found. Issues of protein localized to inclusion bodies in bacteria were addressed.  
PGT 4 is being heterologously expressed in yeast (Pichia pastoris) to allow for protein 
production and analysis. PGT 4 was screened for GT activity with different flavonoid subclass 
representatives and simple phenolics.  
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INTRODUCTION 
 
I. Plant Metabolism 
The complex system of plant metabolism is a popular subject of academic and industrial 
research. The intricate pathways and products of plants have been investigated for reasons of 
pure academic knowledge to applied research in genetic engineering with economic implications 
(Harborne and Simmonds, 1964; Traka and Mithen, 2009; Kiplimo et al., 2012; and ref. therein). 
The plant is a self-sufficient organism comprised of mechanisms to feed, hydrate, and protect 
itself while maintaining a semi-static location in its environment. The primary metabolic 
pathways of plants, concerning their nutrition and growth, have been elucidated with the study of 
plants’ primary metabolites such as carbohydrates, lipids, proteins, and nucleic acids, while 
secondary metabolites and their enzymatic pathways are still undergoing much research 
(Ribéreau-Gayon, 1972; Harborne, 1993; Vaistij et al., 2009; He et al., 2012; and ref. therein). 
The complex role of secondary metabolites in plants is still being investigated. Regarded as 
“waste products” less than fifty years ago, more recent research has found that these chemicals 
help plants interact with their environment and significantly impact a plant’s health and defense 
(Springob and Kutchan, 2009; and ref. therein).  
Adapting over generations by natural selection, plants and their metabolic pathways have 
evolved to better reproduce and protect against the environment and potential predators (Wink, 
2003; and ref. therein). For these reasons, plants contain pathways to produce plant secondary 
products which directly help to increase reproductive success by flavor and pigment production 
and UV petal patterning (Harborne and Boardley, 1983; Owens and McIntosh, 2011; Scora and 
Kumamato, 1983; Kesterson and Hendrickson, 1957; and ref therein).  Secondary plant 
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metabolites are compounds found in all higher plants that also function as a defense against 
herbivores, microbes, viruses, and other harmful entities (Harborne, 1964; Vogt and Jones, 2000; 
Wink, 2003; Ferreyra et al., 2012; and ref. therein). The accumulation of secondary metabolites, 
such as phenylpropanoids, terpenoids, betacyanins, and flavonoids, improves the overall survival 
and reproductive fitness of plant species (Harborne, 1993; Wink, 2003; Vaistij et al., 2009; 
Ferreyra et al., 2012; and ref. therein).    
II.     The Flavonoids 
The McIntosh lab focuses its research 
primarily on one group of secondary metabolites, 
the flavonoids. Flavonoids are derived from the 
amino acid phenylalanine which is formed via the 
Shikimate pathway. The flavonoids are 
subsequently formed via the phenylpropanoid pathway to produce a fifteen carbon structure 
(reviewed in Harborne and Simmonds, 1964; Ribéreau-Gayon, 1972; Winkel-Shirley, 2001; 
Owens and McIntosh 2011). These carbons are arranged by a multi-enzyme pathway into two 
benzene rings connected by a three carbon bridge (Figure 1). This basic structure of flavonoids is 
further modified by enzymes to create the subclasses of flavonoids which include chalcones, 
aurones, flavanones, flavones, isoflavones, dihydroflavonols, flavonols, leucoanthocyanidins, 
and anthocyanidins (reviewed in Harborne and Simmonds, 1964; Owens and McIntosh, 2011).   
These subclasses differ by substitutions in ring composition. For example, flavonoid 3 
hydroxylase (F3H) adds a hydroxyl group to the position 3 of the flavonoid skeleton of 
dihydroflavonols, and flavonol synthase (FLS) creates a double bond on the carbon bridge to 
Figure 1.  Flavonoid Skeleton (Celestino et al., 2003) 
 
7 
 
produce flavonols. The phenylalanine and flavonoid biosynthetic pathways can be seen in Figure 
2 (Winkel-Shirley 2002).  
 
Figure 2. Flavonoid Biosynthetic Pathway (Adapted from Winkel-Shirley 2002) 
All of the subclasses have different functions within the plant and are found in an array of 
different plant species (Harborne and Simmonds, 1964; Springob and Kutchan, 2009; Harborne, 
1993; Winkel-Shirley 2002; and ref. therein). Flavonoids, such as anthocyanidins, are known to 
help in pigment production and therefore have been found most abundantly in the outer 
coverings of fruits or petals of plants (Forkman et al., 1980; Modolo et al., 2009).  However 
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other subclasses can be found in more abundance in the fruit tissue and leaves of plants which 
are consumed by animals (Harborne, 1993; Scora and Kumamato, 1983; Berhow, 1998).  
Quercetin, a flavonol, is one of the most widely distributed flavonoids in the world and can be 
found in many edible plants such as apples and onions (Ribéreau-Gayon, 1972). 
III.    Benefits of Flavonoids on Human Health 
 The flavonoids contain many properties that benefit the health of the plants as well as an 
organism that consumes it (Springob and Kutchan, 2009; and ref. therein).  The presence of 
flavonoids in a healthy diet has made them a popular subject for possible pharmaceuticals or 
medical treatments.  The benefits of these naturally-occurring aromatic secondary plant 
metabolites are extensive and include antioxidant, antiviral, antiallergic, antidiabetic, 
cardioproctective, and anti-carcinogenic characteristics (Rice-Evans et al., 1995; Caltagirone et 
al., 2000; Traka and Mithen, 2009; Toumi, 2009). Thus, the study of the synthesis and regulation 
of flavonoids is vital for economic and clinical reasons.  
 Several clinical trials have been conducted to test possible advantageous effects of 
flavonoids on heart health. The Zutphen Elderly Study, conducted in the Netherlands starting in 
1960, found that flavonoid intake was significantly inversely associated with mortality from 
coronary heart disease in elderly men, ages 65-84 (Hertog and Feskens, 1993). Their flavonoid 
intake was controlled through a diet of tea, onions, and apples, which all contain different 
subclasses of flavonoids. Overall, it was found that flavonoids inhibit the oxidation of low-
density lipoprotein and reduce thrombic tendency (Hertog and Feskens, 1993). Epidemiology 
studies reported a high dietary intake of flavonoids can also reduce the risk of heart disease 
(Knekt et al., 2002). Flavonoids were also found to increase vascular relaxation in porcine 
coronary arteries (Xu et al., 2007).  These findings have furthered flavonoid synthesis research to 
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discover compounds that could be used in pharmaceuticals or in a dietary treatment plan (Vastij 
et al., 2009).  
 Due to their antioxidant effects, flavonoids are used in the production of many medicines 
and supplements (Traka and Mithen, 2009; and ref. therein).  Free radicals are produced by 
normal metabolic processes and/or exposure to other sources such as ultra-violet light or smoke. 
The unpaired electrons on free radical species can cause considerable cell damage and can lead 
to cancer development or other chronic diseases (So et al., 1997; Middleton and Kandaswami, 
1990; and ref. therein). Flavonoids are found to have free radical scavenging abilities due to their 
hydroxyl group substitutions about the flavonoid skeleton (Amic et al., 2003; Rice-Evans et al., 
1995).   
Flavonoids can also help control the proliferation of carcinogenic cells (So et al., 1997; 
and ref. therein).  For example, baicalein, galagin, hesperetin, naringenin, and quercetin were all 
found to have antiproliferative activity against breast cancer cells (So et al., 1997; Caltagirone et 
al., 2000). Flavones and isoflavones have also been found to prevent cancer by maintaining a 
rich diet of these flavonoid compounds (Birt et al., 2001). Intake of flavonoids has been found to 
reduce many types of cancer including lung and breast cancer (Zava and Duwe, 1997; Le 
Marchand et al., 2000; and ref. therein).  
 Flavonoids have also been found to exhibit anti-HIV activity as well as inhibit HIV-I 
reverse transcriptase, protease, and integrase (Wang et al., 2004; Xu et al., 2000). One study 
found baicalin, a flavonoid compound from a Chinese herbal medicine, inhibited HIV infection 
upon viral entry (Li et al., 2000). Some flavonoids have even been used to create drugs for 
chemotherapy of the HIV infection (Vlietinck et al., 1998). These examples only shed a small 
light on the plethora of flavonoid natural products that are used against the HIV infection. Again, 
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this shows that the flavonoids are a popular subject for pharmaceutical research to treat many 
different diseases.  
Evidence has been found to suggest that flavonoids regulate cell function. This leads to a 
significant immune and inflammatory response by flavonoids that aid in secretory processes, 
mitogenesis, cell-cell interactions, and regulation of homoeostasis of the immune system 
(Middleton and Kandaswami, 1992; Traka and Mithen, 2009; and ref. therein). The flavonoids 
will continue to be studied for their health benefits to humans to further elucidate any other 
medicinal implications.  
 
IV.     Glucosylation of Flavonoids  
Over 7,000 naturally-occurring flavonoids have been discovered to date (Harborne and 
Simmonds, 1964; Harborne, 1993; Andersen and Markham, 2006).  The basic structure lends 
itself to substitutions from many types of molecules. Flavonoids can readily go under the 
processes of hydroxylation, acylation, glucosylation, and many other substitutions (Harborne and 
Simmonds, 1964; Ribéreau-Gayon, 1972; Winkel-Shirley, 2001).  In vivo, flavonoids are found 
to be highly substituted; the majority of compounds are present in glycosylated forms (Andersen 
and Markham, 2006).  Each substitution of the flavonoid skeleton changes the chemical 
properties of the compound.  
One of the final steps of flavonoid biosynthesis, glucosylation, is a significant process 
because the substitution of hydrogen from the ring or hydroxyl group for a glucose molecule can 
affect its toxicity, regulate homeostasis, and enhance the solubility of the compound (McIntosh 
and Mansell, 1990; Bowles, 2006; Traka and Mithen, 2009; and ref. therein). The enzyme 
responsible for the transfer of the glucose moiety is called a glucosyltransferase (GT). Over 
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12,000 putative glucosyltransferase sequences  have been collected and appear in various 
databases from different organisms including but not limited to Vitis vinifera, Arabidopsis 
thaliana, and Citrus paradisi, but only around 40 GT sequences have had biochemical 
confirmation of function (Owens and McIntosh, 2009; Masada et al., 2009; Vaistij et al.,  2009; 
and ref. therein). GTs that glucosylate plant natural products and small lipophilic molecules 
belong to the GT 1 family (Vogt and Jones, 2000; Vaistij et al., 2009). Many different types of 
sugars can be transferred by GTs; however, many characterized flavonoid GTs have been found 
to prefer uridine diphosphate glucose (UDP-glucose) for transfer (McIntosh and Mansell, 1990; 
McIntosh et. al., 1990; Owens and McIntosh, 2009; and ref. therein). GTs that are selective for 
UDP-glucose are known as UGTs, and most characterized UGTs have been found to have 
further substrate selectivity to prefer just one subclass of flavonoids (Li et al., 2007; Modolo et 
al., 2007; Owens and McIntosh, 2009; and ref. therein).  
V.    Grapefruit Model System 
 The model plant system used for this research is Citrus paradisi, or grapefruit. The 
grapefruit plant is an ideal subject because it is known to contain many glucosylated flavonoids 
(Scora and Kumamato, 1983; Dugo et al., 2005; Berhow, 1998). Grapefruit is especially rich in 
flavanones and flavones (Owens and McIntosh, 2009; and ref. therein). These subclasses are 
known as early flavonoids as they are produced upstream in the flavonoid biosynthesis pathway 
(Harborne and Simmonds, 1964; Dean, 2003).  Different amounts of flavonoids are found 
throughout all different types of grapefruit tissue and stages (McIntosh and Mansell 1990; 
Jourdan et al 1985; Berhow, 1998; Scora and Kumamato, 1983). In young grapefruit leaves, 40-
70% of the dry weight was found to be the bitter compound naringin (McIntosh and Mansell, 
1990; Jourdan et al., 1985; Kesterson and Hendrickson, 1957). Some speculate that this 
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compound in the young grapefruit tissue has a bitter taste for defense (Del Rio et al., 1998). It 
has been discovered that when a rhamnose sugar is added to naringenin 7-O-glucoside, based on 
the substitution site, it can change the flavor composition to bitter naringin or tasteless narirutin. 
Tasteless linkages are found in non-bitter species, such as Citrus reticulata and Citrus sinensis. 
Both linkages, bitter and tasteless, are found within Citrus paradisi (Frydman et al., 2004; 
Jourdan et al., 1985; Kesterson and Hendrickson, 1957, Barthe et al., 1987, Berhow 1998). The 
effect of glycosylation on taste makes it a popular subject of research for the citrus industry 
(Horowitz and Gentili, 1969; Shaw et al., 1984; Drewnowski et al., 2001; Mansell and McIntosh, 
1991; Mansell et al., 1983; Jourdan et al., 1985; Barthe et al., 1987). 
VI.    Putative Glucosyltransferase 4 
Various putative glucosyltransferase clones studied in our lab, in particular the one 
presented in this research, were obtained from a young grapefruit leaf cDNA library (Roy Sarkar 
et al., 2007). Degenerate primers were designed against the PSPG (Plant Secondary Product 
Glucosyltransferase) box, a forty-four amino acid sequence unique to glucosyltransferases. Smart 
Race RT-PCR was used to amplify 5’ clones, and then clone specific primers were designed to  
“walk out” the sequences and find the 3’ ends (Sibhatu, 2003; Roy Sarkar, 2004; Roy Sarkar et 
al., 2007; Strong, 2005)  All clones had a high identity with other glucosyltransferases within the 
PSPG box region and a low identity outside the PSPG box region (Roy Sarkar et al, 2007).  
Figure 3 shows the PGT 4 with the start and end of PSPG box region marked with arrows.   
 
1     ATG GCA TCC GAA GCC AGC CAG GTT CAC TTT CTC TTG CTT CCT TAC   45 
1     Met Ala Ser Glu Ala Ser Gln Val His Phe Leu Leu Leu Pro Tyr   15 
 
46    TTG GCT CCA GGC CAC TTG ATT CCC ATG TTT GAC ATT GCT AGA TTG   90 
16    Leu Ala Pro Gly His Leu Ile Pro Met Phe Asp Ile Ala Arg Leu   30 
 
91    CTT GCA CAG CAT GGA GCT ATT GTT ACT ATT GTC ACC ACC CCA GTT   135 
31    Leu Ala Gln His Gly Ala Ile Val Thr Ile Val Thr Thr Pro Val   45 
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136   AAT GCG GCA AGG TTC AAA ACA GTG ATT GCT CGT GCA ATA AAA TCC   180 
46    Asn Ala Ala Arg Phe Lys Thr Val Ile Ala Arg Ala Ile Lys Ser   60 
 
181   GGC CTA CAA ATC CGA CTA ATT GAG ATC CAG TTT CCT TGG CAA GAA   225 
61    Gly Leu Gln Ile Arg Leu Ile Glu Ile Gln Phe Pro Trp Gln Glu   75 
 
226   GCA GGA ATA CCT GAA GGT TGT GAG AAT TGT GAC TTG CTT CCT ACA   270 
76    Ala Gly Ile Pro Glu Gly Cys Glu Asn Cys Asp Leu Leu Pro Thr   90 
 
271   ACA GAC TTT GCA AGG TTC ATG AAG TCG CTT CAC ATG CTT CAA CAG   315 
91    Thr Asp Phe Ala Arg Phe Met Lys Ser Leu His Met Leu Gln Gln   105 
 
316   CCT TTT GAA AAT TTG TTC AAA GAG AAA ACT CTT AAG CCC TGC TGC   360 
106   Pro Phe Glu Asn Leu Phe Lys Glu Lys Thr Leu Lys Pro Cys Cys   120 
 
361   ATA ATC TCT GAC ATG TGT TTT CCT TGG ACG GTG GAT ACA GCT GCC   405 
121   Ile Ile Ser Asp Met Cys Phe Pro Trp Thr Val Asp Thr Ala Ala   135 
 
406   AAG TTC AAT GTT CCA AGG ATT ATT TTC CAT GGA TTT TCT TGC TTC   450 
136   Lys Phe Asn Val Pro Arg Ile Ile Phe His Gly Phe Ser Cys Phe   150 
 
451   TGT CTC TTC TGT CAT CAC CTC TTG GGT GTT TCA AAG GTT CAC GAG   495 
151   Cys Leu Phe Cys His His Leu Leu Gly Val Ser Lys Val His Glu   165 
 
496   AAT GTT ACT TCT GAT TCA GAG TAC TTT AAT ATA CCT GGA TTG CCT   540 
166   Asn Val Thr Ser Asp Ser Glu Tyr Phe Asn Ile Pro Gly Leu Pro   180 
 
541   GAT CAC ATT CAA TTT ACT AAA GTT CAA TTA CTA ATA TCC AAG CGG   585 
181   Asp His Ile Gln Phe Thr Lys Val Gln Leu Leu Ile Ser Lys Arg   195 
 
586   GAT GAT GAC CGT AAA GAG CTT CGA GAG CAA ATT TTG GCG GCC GAT   630 
196   Asp Asp Asp Arg Lys Glu Leu Arg Glu Gln Ile Leu Ala Ala Asp   210 
 
631   AAG AAA ACA TAC GGC GCG ATT ATA AAT ACC TTC GAA GAG CTA GAG   675 
211   Lys Lys Thr Tyr Gly Ala Ile Ile Asn Thr Phe Glu Glu Leu Glu   225 
 
676   TCG CCA TTT ATT GAA AAC TAC AAA AAA GCC GAA CAA GGA AAA GTT   720 
226   Ser Pro Phe Ile Glu Asn Tyr Lys Lys Ala Glu Gln Gly Lys Val   240 
 
721   TGG TGC ATC GGC CCT GCT TCG CTG TGC AAC AAA GAG CCC ATA GAC   765 
241   Trp Cys Ile Gly Pro Ala Ser Leu Cys Asn Lys Glu Pro Ile Asp   255 
 
766   AAG GCA GAG AGA GGT AAA ACA GCA TCA ATT GAT GTT CCT GAA TGC   810 
256   Lys Ala Glu Arg Gly Lys Thr Ala Ser Ile Asp Val Pro Glu Cys   270 
 
811   TTA ACA TGG CTT GAT TCA CAG CAG CCA AGC TCA GTA GTC TAT GTT   855 
271   Leu Thr Trp Leu Asp Ser Gln Gln Pro Ser Ser Val Val Tyr Val   285 
 
856   TGT CTT GGA AGC ATC TGT AAC TTG CCA TCT TCA CAA CTT ATA GAG   900 
286   Cys Leu Gly Ser Ile Cys Asn Leu Pro Ser Ser Gln Leu Ile Glu   300 
 
901   CTC GGT TTA GGC CTT GAA GCA TCT AAC AAA CCG TTT GTT TGT GTT   945 
301   Leu Gly Leu Gly Leu Glu Ala Ser Asn Lys Pro Phe Val Cys Val   315 
 
946   ATC AGG GGA GTG AGT AAA TTA GAA GCA TTA GAG AAG TGG CTT GTA   990 
316   Ile Arg Gly Val Ser Lys Leu Glu Ala Leu Glu Lys Trp Leu Val   330 
 
991   CAA GAA AAT TTT GAA GAA AGG ATT AAA GGA AGA GGC CTA TTG ATT   1035 
331   Gln Glu Asn Phe Glu Glu Arg Ile Lys Gly Arg Gly Leu Leu Ile   345 
 
1036  CGG GGT TGG GCA CCA CAA GTA TTG ATA TTA TCA CAC CCT GCA GTC   1080 
346   Arg Gly Trp Ala Pro Gln Val Leu Ile Leu Ser His Pro Ala Val   360 
 
1081  GGA GGG TTC TTA ACG CAT TGC GGC TGG AAT TCA TCT CTG GAA GGG   1125 
361   Gly Gly Phe Leu Thr His Cys Gly Trp Asn Ser Ser Leu Glu Gly   375 
 
1126  ATA TCA GCT GGG GTT CAA ATG CTT ACA TGG CCA CTC TTT GCA GAC   1170 
376   Ile Ser Ala Gly Val Gln Met Leu Thr Trp Pro Leu Phe Ala Asp   390 
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1171  CAA TTT TGC AAT GAG AAG TTG ATT GTG AAT GTT TTA AGG ATT GGT   1215 
391   Gln Phe Cys Asn Glu Lys Leu Ile Val Asn Val Leu Arg Ile Gly   405 
 
 
1216  GTG AGT GTT GGA GTG GAA GTT CCA ATG AAT TTT GGA GAA GAA GAG   1260 
406   Val Ser Val Gly Val Glu Val Pro Met Asn Phe Gly Glu Glu Glu   420 
 
1261  AAG ATT GGA GTA TTG GTG AAT AAG GAA AAT GTC AAA ACG GCT ATA   1305 
421   Lys Ile Gly Val Leu Val Asn Lys Glu Asn Val Lys Thr Ala Ile   435 
 
1306  AAC ATA CTG ATG GAT GAT GGA GAG GAA AGA AAT GCG AGA AGA AGT   1350 
436   Asn Ile Leu Met Asp Asp Gly Glu Glu Arg Asn Ala Arg Arg Ser   450 
 
1351  GCC AGA GAG TTT GGA GAG TTG GCT AAA AGA GCT ATA GAT GAA GGT   1395 
451   Ala Arg Glu Phe Gly Glu Leu Ala Lys Arg Ala Ile Asp Glu Gly   465 
 
1396  GGA TCT TCC TAT AAC AAC GTC GAA TTA TTT ATG CAA GAT ATC ATG   1440 
466   Gly Ser Ser Tyr Asn Asn Val Glu Leu Phe Met Gln Asp Ile Met   480 
 
1441  CAA CAG CCG AGC TCA GAA GTG ATT TAA   1467 
481   Gln Gln Pro Ser Ser Glu Val Ile End 
 
Figure 3. Amino Acid Sequence of PGT 4 with arrows denoting the start and end of the Plant Secondary      
Product Glucosyltransferase (PSPG) Box.  
 
 
The focus of this research is the study of one putative glucosyltransferase clone, PGT 4 
(Figure 3). The PGT 4 sequence consists of 1467 base pairs, and the PGT 4 protein has a 
predicted molecular weight of 54 kD. This size is within the normal range observed for the 
majority of plant GTs (McIntosh and Mansell, 1990; McIntosh et al., 1990; Durren and 
McIntosh, 1999; Owens and McIntosh, 2009; and ref. therein).     
Once the 5’ and 3’ ends of the PGT 4 clone had been determined, it was then cloned into 
a bacterial vector, pCR
®
 4-TOPO
®
 (Invitrogen) by previous researchers, Christy Strong and 
Leslie Epling (Strong, 2005; Epling, 2007). Josephat Asiago cloned PGT 4 into the pCD1 vector, 
a modified version of the pET-32A cloning vector with an engineered thrombin cleavage site to 
remove the tags for better purification upon expression (Winkel, VA Tech). Once the presence of 
PGT 4 was confirmed within pCD1, Asiago screened for flavonoid glucosyltransferase activity 
of PGT 4 expressed in E.coli, but little to no activity was found.  Inclusion bodies, vacuoles in 
bacteria that store expressed proteins, rendered much of the expressed protein insoluble and 
unable to be active.  Thus, PGT 4 has now been cloned into the pPICZA vector (Invitrogen; 
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Sanje Roje, WSU) and transformed into Pichia pastoris, a eukaryotic system, to eliminate the 
problems with inclusion bodies and insoluble protein and to again test for flavonoid 
glucosyltransferase activity. This research was conducted with the hypothesis that PGT 4 would 
glucosylate flavonoid substrates, acting as a flavonoid glucosyltransferase.  
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MATERIAL AND METHODS 
I. Materials 
Chemicals and Reagents 
 Agarose, agar, yeast extract, tryptone, yeast nitrogen base powder, and sodium chloride 
were used in making liquid media (Fisher Scientific, Fairlawn, NJ).  Ampicillin (Fisher 
Scientific) and zeocin™ (Research Products Int. Corp., Mt. Prospect, IL) were needed to make 
media and agar plates with antibiotics.  Ethidium bromide, EtBr (10 mg/mL), was used to 
visualize DNA in gel electrophoresis. One kb DNA Ladder (Fisher Scientific) was utilized to 
verify DNA band lengths.  Go Taq DNA Polymerase, 5 X green/colorless buffer, and 
deoxyribonycleotide triphosphates (dNTPs) were used for polymerase chain reactions (Promega 
Madison, WI).  T4 DNA ligase enzyme, ligation buffer, restriction enzymes Apa I, Kpn I, EcoRI, 
Not I (Promega, Madison, WI), and clone specific primers (Integrated DNA Technology, 
Coralville, Iowa) were utilized for clone reconstruction and DNA cloning. Tris base,  
tetramethylethelynediamine (TEMED, electrophoresis grade), ammonium persulfate (APS), 40% 
acrylamide solution (acrylimide:bis-acrylamide, 19:1), coomassie brilliant blue, and glacial 
acetic acid were purchased from Fisher Scientific. Nitrocellulose membrane (0.45 μm pore size) 
was bought from Thermo Fisher Scientific, Waltham, MA. Whatman chromatography paper 
(3MM CHR), 5-bromo-4-chloro-3’-indolyphosphate p-toludine salt (BCIP) and nitro-blue 
tetrazolium chloride (NBT), (Fisher Scientific) were used for protein gels and Western blots. 
Monoclonal mouse c-myc antibody and goat, anti-mouse IgG alkaline phosphatase (AP) 
conjugates were purchased from Novagen (Madison, WI).  The Mini-PROTEIN Tetra gel 
electrophoresis system, micropulser cuvettes, and Silver Stain Kit were purchased from Bio-rad 
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(Hercules, CA).  Lyticase enzyme (from Arthobacter leutus) and acid-washed glass beads (pore 
size 0.5 mm) were purchased from Sigma Aldrich (St. Louis, MO). Coomassie® R-250 for 
protein gel staining was purchased from Life Technologies™ (Grand Island, NY).  
Cells and Vectors 
 The pCD1 vector was obtained from Brenda Winkel of the Virginia Polytechnic Institute 
and State University (Blacksburg, VA). The pCR
®
 4-TOPO
®
 vector and One Shot
®
 Top Ten 
Chemically Competent Cells were purchased from Invitrogen (Carlsbad, CA). The pPICZA 
vector and X33 parent strain of Pichia pastoris were a gift from Sanja Roje of Washington State 
University (Pullman, WA). Competent yeast cells were prepared following the protocol from the 
Invitrogen Easy Select™ Pichia Expression Kit.  
Kits 
 The QIAprep
®
 Spin Miniprep Kit was purchased from Qiagen (Valencia, CA).  The 
Wizard
®
 SV Gel and PCR Clean-Up System was purchased from Promega. The Quantum Prep
®
 
Plasmid Midiprep Kit was purchased from BIO-RAD. The TOPO TA Cloning
®
 Kit was 
purchased from Invitrogen. 
Buffers 
 All of the following buffers were prepared by recipes in Appendix A.  TAE (Tris-Acetate 
EDTA) was prepared for DNA electrophoresis. One molar potassium phosphate (pH 6) was 
prepared for growth media. TANK Buffer (pH 8.3), TBS buffer, AP buffer (pH 9.5), 1 mM 
PMSF (phenylmethylsulfonyl fluoride), 1 mM EDTA (ethylenediaminetetracetic acid), breaking 
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buffer transfer buffer, blocking solution, developing solution, and stop buffer were all prepared 
for SDS-PAGE and Western blot analysis. 
Culture Media 
 Low salt LB (Luria-Bertani) liquid media and LB agar plates were prepared as described 
in Appendix B. YPD (yeast, peptone, dextrose) liquid media and YPDS (yeast, peptone, 
dextrose, and sorbitol) agar plates were prepared as described in Appendix B. Buffered glycerol-
complex media (BMGY) and buffered methanol-complex media (BMMY) were prepared as 
described in Appendix B.  
Flavonoids and Phenolic Substrates for Enzymes Assays 
 Naringenin, hesperitin, eriodictyol, isosakuranetin, apigenin, luteolin, diosmetin, 
scutallerein, kaempferol, quercetin, fisetin, gossypetin, 4’ methoxyflavonol, 4’-acetoxy-7-
hydroxy-6-methoxy isoflavanone were purchased from Sigma and Indofine.  
II. Methods  
Clone Specific Primer Design 
 Based on the BioEdit (Ibis Biosciences, Carlsbad, CA) file received from Dr. Daniel 
Owens, clone specific primers for putative glucosyltransferase 4 were designed in order to 
amplify the sequence by polymerase chain reaction (PCR). The primers were designed as shown 
below (Table 1).  
Table 1. PGT 4 Clone Specific Primer Sequences for PCR Amplification. The bolded 
nucleotides correspond to the restriction enzyme cutting site in each primer.  
Primer Sequence 
Rest. 
Enzyme  
Annealing 
Temp. 
CSP 144 F 5’ CAT GGG TAC CAT GGC ATC CGA AGC CAG CCA 3’ Kpn I 62.3 
o
C 
CSP 145 R 5’ CGC GGG CCC AAT CAC TTC TGA GCT CGG CTG 3’  Apa I 64.3 
o
C 
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The restriction enzymes chosen were to help facilitate cloning into the pPICZA vector as 
Apa I and Kpn I are located within the vector’s multiple cloning site (Invitrogen). The primers 
were ordered from Integrated DNA Technology through the ETSU Quillen College of Medicine 
Molecular Biology Core Facility (Johnson City, TN).  
Low Salt LB Liquid Media Culture 
 E.coli cultures were grown from Josephat Asiago’s glycerol stocks of PGT 4 stored at  
-80
o
C.  Various glycerol stocks were chosen to verify the sequence of PGT 4. Low salt LB liquid 
media was made according to the recipe in Appendix B. The glycerol stocks were saved in the 
pCR® 4-TOPO® vector (Invitrogen) which has an ampicillin resistance. Ampicillin was added 
to the LB media to produce a final concentration of 100 mg/L. LB liquid media with antibiotic 
was inoculated with a dab of glycerol stock using an autoclaved toothpick or pipet tip. Cultures 
were inoculated overnight, 12-16 hours, in a New Brunswick Shaker Incubator at 250 rpm at 37 
o
C.  
Isolation of DNA Plasmid 
 The QIAprep® Spin MiniPrep Kit was used to isolate DNA plasmid from the LB liquid 
media cultures. Five milliliters of culture were used for each MiniPrep. The cells were 
centrifuged in autoclaved centrifuge tubes (Fisher Scientific) in a Sorvall® Biofuge pico 
microcenterfuge, and the Qiagen protocol was followed to isolate the DNA plasmid. Fifty μL of 
DNA was isolated from each MiniPrep and was labeled and stored at -20 
o
C.  
DNA Gel Electrophoresis  
 Thirty mL 0.8% agarose gels were made to verify the presence of plasmid DNA in the 
MiniPreps and to verify the vector length by comparison to the 1 kb DNA ladder (See recipe in 
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Figure 4. pCR
®
 4-TOPO
®
 vector map (Invitrogen) 
Appendix C).  Two and a half μL ethidium bromide (10 mg/mL) were added to each gel before 
solidification in order to view the DNA with a UV illuminator. The gel was cooled in an 
electrophoresis cell (Owl Separation Systems, Inc., Portsmouth, NH) and each well was loaded 
with 6μL of a mixture including 2μL DNA, 1μL 6Xdye, and 3μL distilled water in each lane. 
The electrophoresis cell was run for one hour at 100 volts. The gels were viewed in an Epi Chem 
II Darkroom from UVP Bioimaging Systems and images saved as computer files for later use.  
DNA Sequencing 
 Once the presence of DNA plasmid in the MiniPreps was confirmed, an aliquot was sent 
to the Molecular Biology Resource Facility of the University of Tennessee in Knoxville, TN for 
sequencing. The DNA sequencing results were sent via electronic mail in BioEdit files. The files 
were compared with the PGT 4 sequence obtained from Dr. Daniel Owens. Upon alignment of 
all the glycerol stocks sent for sequencing, it was found that not one of the glycerol stocks 
contained the full length PGT 4 sequence. All of the stocks were partial clones.  
Reconstruction of Full-length PGT 4  
 Different glycerol stocks from Josephat Asiago 
were grown. DNA plasmid was isolated and sent 
for sequencing to try to find a stock of the full 
length PGT 4 clone. After sequencing several 
glycerol stocks and finding only partial clones, 
glycerol stocks from Christy Strong were grown, 
and the isolated DNA was sequenced. The 
glycerol stocks labeled 181.2A and 155.1A 
contained partial PGT 4 clones in the pCR® 4-TOPO® vector, but each contained significant 
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pieces. A strategy was devised to cut and ligate the pieces together.  To perform a directed 
ligation, it is necessary to have a unique cutting site. However, it was discovered that only one 
enzyme could cut the two partial clones in the desired range to ligate them together.  A challenge 
arose. EcoRI was needed to internally cut the partial clones, but it is located on both sides of the 
pCR
®
 4-TOPO
®
 vector multiple cloning site (Figure 4).  
Primer Design  
 With the multiple EcoRI cutting sites within the pCR
®
 4-TOPO
®
 vector multiple cloning 
site, the PGT 4 partial clones (181.2A and 155.1A) needed to be amplified outside the pCR
® 
4-
TOPO
®
 vector. Thus, primers were designed to PCR amplify the partial clones out of their 
vector, and restriction enzymes were chosen to easily clone PGT 4 into pPICZA after the 
reconstruction. Figure 5 below shows the schematic for the reconstruction of PGT 4 with the 
designed primers. Table 2 shows the clone specific primer sequences designed to PCR amplify 
the pieces out of the pCR
®
 4-TOPO
®
 vector. 
 
Figure 5. Plan for the Reconstruction of PGT 4 Four clone specific primers were designed against the 
partial clones to amplify them out of the pCR
®
 4-TOPO
® 
vector. The internal EcoRI site was used to 
ligate the two pieces together within an empty pCD1 vector.  
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Table 2. Primer Design for PCR Amplification out of pCR
®
 4-TOPO
®
 vector.  
              Bolded bases represent restriction enzyme cutting sites for each primer.  
 
  The strategy to reconstruct the PGT 4 clone was to PCR amplify the two partial clones 
and insert the digested, gel purified PCR product into an empty pCD1 vector one at a time to 
reconstruct the PGT 4 clone successfully. Below is a flow chart of the plan used to reconstruct 
the PGT 4 clone (Figure 6).  
 
            Figure 6.  Plan for the Reconstruction of PGT 4. The flow chart shows the process 
 used to reconstruct the PGT 4 clone from the two partial clones in an empty pCD1 vector.  
 
 
 
Primer Sequence 
Rest. 
Site 
Annealing 
Temp. 
CSP 144 F 5’ CATG GGTACC ATG GCA TCC GAA GCC AGC CA  3’ KpnI 62.3 
o
C 
CSP 149 R 5’ GAT GAATTC CAG CCG CAA TGC GTT AAG AAC CCT 3’ EcoRI 64.8 
o
C 
CSP 150 F 5’ CTG GAATTC ATC TCT GGA AGG GAT ATC AGC TGG GGT TCA 3’ EcoRI 65.8 
o
C 
CSP 151 R 5’ CGC GCGGCCGC AAT CGC TTC TGA GCT CGG CTG TTG 3’ NotI 61.6 
o
C 
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PCR Amplification  
 To amplify the 181.2A and 155.1A partial clones via PCR, the following contents were 
added into a PCR tube: 2.5 μL of 1000 fold dilution of MiniPrep DNA of 181.2A or 155.1A 
(0.001μg/μL), 10μL of 5X green Go-Taq buffer, 2.5 μL of 20μM sense primer, 2.5 μL of 20μM 
antisense primer, 1.0 μL of Go-Taq polymerase, 31μL of distilled, sterile water to total a 50 μL 
PCR reaction. The annealing temperature varied with the primers, which have relatively close 
annealing temperatures to avoid PCR mistakes. The PCR reaction was carried out in the 
MyCycler thermocycler (Bio-Rad), which was set up with the protocol below (Table 3).  
 
Table 3. Temperature Protocol for Polymerase Chain Reaction 
Step Temperature (
o
C) Time 
1 94 1 minute 
2 94 30 seconds 
3 60 30 seconds 
4 72 2 minutes 
5 72 3 minutes  
 
Gel Extraction and Purification 
 After the PCR reaction was complete, the PCR products were loaded into lanes of a 0.8% 
agarose gel, as previously described. The gel electrophorised for an hour at 100 volts and was 
viewed on a Spectroline
®
 Transilluminator with a 302 nm UV light (Westbury, NY).  A 
sterilized metal razor was used to excise the desired band out of the agarose gel. The desired 
181.2A product was 1100 base pairs, while the 155.1A piece was around 350 base pairs. Their 
lengths were determined in comparison to the 1 kb ladder, run in the first lane of the gel. The 
bands were put into separate sterile micro centrifuge tubes, labeled, and DNA extracted using the 
protocol of the Wizard
®
 SV Gel and PCR Clean-Up System (Promega Madison, WI). The DNA 
was eluted into 50 μL of sterile, distilled water and stored at -20 
o
C.  
 
30 X 
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Digestion of PCR Product and pCD1 vector 
 The DNA concentrations of the purified gel bands were tested using the NanoDrop 
spectrophotometer (Thermo Scientific). For each digestion, 1 μg of DNA was used. The 181.2A 
PCR product and empty pCD1 vector were both digested with KpnI and EcoRI. To set up a 
digestion, 1 μg of DNA, 1μL of each enzyme, 2 μL enzyme-specific 10Xbuffer, and 0.2 µL BSA 
for stabilization was added to a varied amount of sterile, distilled water to a total reaction volume 
of 20 μL. Digestions were incubated at 37 
o
C in a water bath or incubator for three hours. The 
digestion was halted by putting the reactions in the 65
 o
C water bath for five minutes. The 
digestion products were combined with 4 μL of 6Xdye and added to the lanes of an agarose gel. 
The desired bands were extracted and purified as discussed previously.  
Ligation of 181.2A into the pCD1 vector 
 The concentration of the purified, digested DNA was tested using the NanoDrop. The 
insert, 181.2A, had a concentration of 8.1 ng/ μL, and the vector, pCD1, had a concentration of 
17.9 ng/μL. These concentrations were used to setup a ligation of the two pieces to make a 
circular DNA plasmid. The following calculations were made using an online ligation calculator 
(Collins, 2011: http://django.gibthon.org/tools/ligcalc/).  The three ratios were used to optimize 
ligation conditions. Having a higher concentration of insert:vector is useful when performing a 
ligation. The ligation mixtures were added to sterile PCR tubes and left at 4 
o
C overnight. For 
each ligation, the insert and vector had varying concentrations thus the ratios shown may seem 
skewed.  
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Table 4. Ligation Ratios for Insertion of 181.2A into pCD1 
Ratio (Insert:Vector) 1:1 3:1 6:1 
Insert DNA (µL) 4.1 8.2 10 
Vector DNA (µL) 10 6.8 4.1 
Ligase (µL) 1.0 1.0 1.0 
Ligase Buffer (µL) 4.0 4.0 4.0 
Sterile, distilled water (µL) 0.9 0.0 0.9 
 
 
Transformation of Ligated 181.2A and pCD1 
 Once the ligated product had been at 4 
o
C for at least twelve hours, a transformation was 
performed. Following the Invitrogen protocol for One Shot
®
 Top Ten Chemically Competent 
Cells, the cells were thawed and 10 μL of ligated product of each ratio was added to a different 
tube of Top 10 cells. A control of undigested vector plasmid was also inoculated into a tube of 
competent cells. The cells were incubated on ice for 30 minutes and then heat shocked for 30 
seconds at 42 
o
C.  Then, 250 μL of low salt LB media was added to each tube, and they were 
shaken for an hour at 225 rpm at 37 
o
C.  One hundred μL of each tube was plated with a sterile 
tool onto LB agar plates with an ampicillin concentration of 100mg/L. (See Appendix B for LB 
agar plate recipe.) The LB agar plates were kept at 37
 o
C overnight and checked for colonies the 
next day.  
PCR Check for Insertion of 181.2A 
 A test was performed to confirm the presence of 181.2A in pCD1 before isolated DNA 
plasmid was sent off for sequencing. Four colonies were found on the 3:1 ratio plate the next 
day. An autoclaved pipet was used to collect cells from each colony and diluted into 10 μL to use 
as DNA template for the PCR reaction. A PCR reaction was setup by loading a PCR tube with 1 
μL of 1000 fold dilution of MiniPrep DNA of pCD1+181.2A (0.001μg/μL), 2 μL of 5X green 
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Go-Taq buffer, 0.5 μL of 20μM sense primer, 0.5 μL of 20μM antisense primer, 1.0 μL of Go-
Taq polymerase, 5 μL of distilled, sterile water to total a 10 μL PCR reaction. The PCR reaction 
was run with an annealing temperature of 60
 o
C, and 2 μL of 6Xdye was added to the PCR 
product and loaded into lanes of a 0.8% agarose gel. Illumination of the gel showed bands at 
1100 bp in two of the four colonies suggesting the presence of 181.2A insert in pCD1. These 
colonies were inoculated into LB liquid media with amp (100mg/L) and grown overnight at 37 
o
C and 250 rpm. Plasmid DNA was isolated the next day and sent to UTK for sequencing. 
Insertion of 155.1A into pCD1+181.2A vector  
 Upon confirmation of the first insert, the 155.1A PCR product and the pCD1+181.2A 
vector were digested with EcoRI and NotI to insert the second piece and reconstruct the PGT 4 
clone. The same digestion protocol was followed as discussed previously. The 20 μL digestion 
was loaded into a well of a 0.8% agarose gel. After running the gel at 100 volts for an hour, 
correct bands were extracted and purified. The concentrations of the vector and 155.1A insert 
were found using the Nano Drop method. The partial clone, 155.1A, was 7.3 ng/
 
μL, and the 
vector+181.2A was 6.1 ng/μL. A ligation was set up between the two pieces using an online 
ligation Calculator (Collins, 2011; http://django.gibthon.org/tools/ligcalc/). To a sterile PCR tube 
the following was added: 4 µL ligase buffer, 1 μL ligase, 10 μL vector, 1.1 μL insert, and 3.9 μL 
distilled water. The ligation was incubated overnight at 4
o
C.  A transformation was performed 
the next day following the same protocol as discussed above. LB agar plates with transformants 
were left at 37 
o
C overnight for colonies to grow. Nine colonies were found the next day and 
were tested to confirm the insertion of the 155.1A piece. The same protocol for a PCR was used 
as before. When the gel with PCR products was illuminated one colony had the full 1467 base 
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pair sequence of PGT 4. This colony was inoculated into LB amp (100mg/L) media and grown 
overnight. The DNA plasmid was isolated the next day and sent for sequencing at UTK. The 
sequencing results confirmed the reconstruction of full-length PGT 4 in the pCD1 vector.  
Cloning into the pPICZA vector 
 Upon the reconstruction of PGT 4, the clone was able to be cut out of the pCD1 vector 
and inserted into the pPICZA vector to be transformed into yeast. The restriction enzymes 
chosen to create the primers were chosen with the pPICZA multiple cloning site in mind. Thus, 
the sense and antisense primers of the newly reconstructed PGT 4 sequence included KpnI and 
Not I sites. The same sites were also found in pPICZA in a manner in which PGT 4 could be 
directionally cloned into pPICZA without having to design new primers.  
 To clone into pPICZA, the same processes were used as in the case of pCD1. The pCD1 
vector containing the PGT 4 sequence was digested with KpnI and NotI to isolate the PGT 4 
band. Empty pPICZA vector was also digested with KpnI and NotI. The vector and PGT 4 insert 
bands were extracted and purified. Then, an online ligation calculator was used to setup the three 
ratios for ligation (Collins, 2011; http://django.gibthon.org/tools/ligcalc/). The ligation set up is 
detailed in Table 5.  
Table 5. Ligation of PGT 4 and pPICZA 
Ratio (Insert:Vector) 1:1 3:1 6:1 
Insert DNA (µL) 6.5 10.0 10.0 
Vector DNA (µL) 8.5 4.3 2.2 
Ligase (µL) 1.0 1.0 1.0 
Ligase Buffer (µL) 4.0 4.0 4.0 
Sterile, distilled water (µL) 0.0 0.7 2.8 
 
The next day, the ligation products were transformed into One Shot® Top 10 Chemically 
Competent Cells. After incubating for 24 hours at 37 
o
C, there were 12 colonies on the three 
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plates. Following a PCR Check, it was found that five colonies had the PGT 4 sequence 
successfully inserted into the pPICZA vector. These five colonies were inoculated into LB zeocin 
(25mg/L) media and grown overnight. The DNA plasmid was isolated by MiniPrep the next day 
and sent to UTK for sequencing. The sequencing results showed that the PGT 4 sequence had 
been inserted correctly; however, the myc epitope and polyhistidine tags of the pPICZA vector, 
directly following the 3’ end of the PGT 4 insertion, were out of frame. The myc epitope and 
polyhistidine tags are essential for enzyme purification, thus it was imperative that the codons 
encoding the amino acids to make these tags were in frame. A single base pair insertion was 
needed to bring the tag sequences in frame. To keep the tags in frame, the clone specific primer 
needed to be a multiple of three to not frameshift the tags in the pPICZA vector sequence 
following PGT 4. Figure 7 shows the sequence before and after the single insertion.  
 
Primer Modification for Addition of Base Pair 
 Two new primers were designed to amplify the PGT 4 sequence to be in frame within 
pPICZA.  The 5’ primer sequence (CSP 163F) was the same as the original CSP 144F with a few 
changes.  The beginning first three base pairs were altered to correspond with the pPICZA vector 
to help anneal the primer to the sequence for amplification. Also, additional base pairs were 
added at the end of the 5’ primer sequence to match the melting temperature of the 3’ primer and 
increase probability of correct PCR amplification. Only one base had to be added to the 3’ 
primer sequence (CSP 164R) to frameshift the tags (Table 6). Thus, using the original primer 
design of CSP 151 R,  one “G”  was added directly after the final codon of the PGT clone, an 
isoleucine, and directly before the Not I restriction site of the clone specific primer. Figure 7 
shows the sequence before and after the single insertion. 
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Figure 7. Frameshift in purification tag sequences due to clone specific primer.  
A. This figure shows the sequence with out-of-frame tags. The presence of multiple isoleucines 
in the second line instead of the histidine tag is seen. B. This figure shows the sequence with the 
insertion of a “G” at base pair 1465. This insertion caused the tags to be in frame and the 
histidine tag is clearly seen on the second line followed by the stop codon 
 
 
Table 6. This table displays the newly designed primers to amplify PGT 4 to be in frame within 
pPICZA. The bolded base pair shows the insertion. The 3’ primer is designed as the 
complementary sequence. Thus, the addition of a “C” within the primer sequence will result in 
the addition of a “G” into the sequence to frameshift the sequence following the 3’ end that 
codes for vital tags to aid in identification and purification of the protein.  
 
 
PCR Amplification of Recombinant PGT 4 
 
 PCR amplification was performed with the newly designed primers (Table 6). Three PCR 
tubes were loaded with: 12.5 μL 2 X PCR Master Mix (see Appendix B for recipe), 0.5 μL CSP 
163 F, 0.5 μL CSP 164R, 1000X isolated PGT 4 in pPICZA plasmid (the correct but out of 
Primer Sequence 
Rest. 
Enzyme 
TM 
(
o
C) 
CSP 163 F 5’ATC GGT ACC ATG GCA TCC GAA GCC AGC CAG GTT 3’ KpnI 62.3 
CSP 164 R 5’ CTG GCG GCC AAT CAC TTC TGA GCT CGG CTG TTG CA 3’ NotI 64.3 
A 
B 
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frame sequence), and 11.25 µL sterile, distilled water. The reactions were inserted into the 
Eppendorf thermocycler and run with the same protocol as in Table 3. The PCR products were 
loaded onto a 0.8% agarose gel and run at 100 volts for 1 hour. The bands were visualized with 
UV light and extracted from the gel using a sterile blade. The PCR product was purified using 
the protocol of the Wizard
®
 SV Gel and PCR Clean-Up System (Promega). The DNA was eluted 
into 50 μL of sterile, distilled water and stored at -20 
o
C.   
TOPO TA Cloning of PGT 4  
 
 The PCR product was used for TOPO TA Cloning
®
 following the Invitrogen protocol: 4 
µL of PCR product was mixed with 1 µL empty TOPO 
®
 vector and 1 µL TOPO 
® 
salt solution 
and incubated at room temperature for 30 minutes. Two µL of this solution were added to a 
thawed tube of One Shot
®
 Top 10 Chemically Competent Cells. The cells were incubated on ice 
for 5 minutes, heat shocked for 30 seconds in a 42 
o 
C water bath, and then incubated on ice for 2 
minutes. With this protocol, the PCR product is rapidly ligated into the vector and does not need 
an extended incubation period. After adding 250 µL LB media, the cells were shaken for an hour 
at 225 rpm and 37
 o
C.  Varying amounts of the sample (25, 50, 100, 200 µL) were plated onto 
LB amp (100mg/L) agar plates and incubated at 37
 o
C overnight. A positive control was also 
conducted using 1 µL PUC19 in an additional tube of One Shot
®
 Top 10 Chemically Competent 
Cells. The next day, four colonies were found on the selective LB plates. The insertion of the 
PCR product was confirmed by a PCR screen using the new clone-specific primers, CSP 163F 
and CSP 164R (Table 6).  
Cloning into pPICZA with PGT 4 Base Insertion 
 A digestion of PGT 4 in TOPO and empty PICZA plasmid was conducted with KpnI and 
NotI. With the same setup as mentioned before, the digestions were left at 37
 o
C for three hours, 
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and then placed in the 65
 o
C water bath for five minutes to stop the reaction. The digestion 
products were loaded onto a 0.8% agarose gel and run at 100 volts for an hour. The desired 
bands were extracted and purified using the protocol of the Wizard
®
 SV Gel and PCR Clean-Up 
System (Promega). The DNA was eluted into 50 μL of sterile, distilled water and stored at -20 
o
C. The concentrations of the pPICZA vector and PGT 4 insert were measured using the 
NanoDrop and found to be 11.9 ng/μL and 2.9 ng/μL, respectively. A ligation reaction was set 
up using an online ligation calculator (Collins, 2011; http://django.gibthon.org/tools/ligcalc/) and 
incubated at 4
o
C overnight (Table 7).  
Table 7. Ligation of pPICZA and PGT 4 with base insertion 
Ratio (Insert:Vector) 1:1 3:1 6:1 
Insert DNA (µL) 9.8 10.0 10.0 
Vector DNA (µL) 5.2 1.8 0.9 
Ligase (µL) 1.0 1.0 1.0 
Ligase Buffer (µL) 4.0 4.0 4.0 
Sterile, distilled water (µL) 0.0 3.2 4.1 
 
 The ligated products were transformed into OneShot® Top 10 Chemically Competent 
Cells using the manufacturer’s protocol (Invitrogen).  Each plate had a large number of colonies. 
Sixteen were chosen at random; this is the number that can fit in the lanes of one agarose gel 
with a negative and positive control and two lanes of 1 kb ladder. Of these sixteen colonies tested 
with PCR, only two had a band at around 1500 signifying the presence of the PGT 4 insert. The 
colonies were inoculated into LBZeocin (25mg/L) media and grown overnight. The DNA plasmid 
was isolated by MiniPrep and sent for sequencing. The results from UTK showed that the 
insertion was successful and that the myc epitope and polyhistidine tags of pPICZA were in 
frame.  The full PGT 4 sequence with tags in frame is shown in Figure 8. 
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Isolation of DNA Plasmid for Linearization 
 To transform PGT 4 into yeast, 5-10 μL of linearized DNA is required (EasySelect
TM
 
Pichia Expression Kit). To obtain a sufficient amount of DNA to linearize, a Quantum Prep
®
 
Plasmid Midiprep was performed following the manufacturer’s protocol (BIO-RAD). A 5 mL 
culture of a single colony of in-frame PGT 4 pPICZA was grown in LBzeocin (25mg/L) at 37
o
C 
and 250 rpm overnight. The small culture was then inoculated into 45 mL more of selective 
media and grown accordingly. The 50 mL culture was harvested using a Sorvall
®
 RC-5B 
centrifuge. The BIO-RAD protocol was followed to isolate the plasmid, and 600 μL eluted DNA 
was stored at -20
o
C.  
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Figure 8. DNA and translated amino acid sequence of PGT 4 in frame with 
the identification and purification tags within pPICZA. The last line shows the 
His tag and stop codon confirming the correction.  
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Linearization of Plasmid DNA 
 The Invitrogen manual recommends the use of three restriction enzymes: Sac I, Pme I, or 
BstXI to linearize the pPICZA vector. These enzymes only cut the vector once. A restriction 
enzyme map was made for the PGT 4 sequence to see if it contained any internal cutting sites for 
any of these three enzymes. PGT 4 had an internal cutting site for Sac I. PGT 4 did not contain 
internal cutting sites for Pme I or Bst XI. Either could have been used; however, BstXI was used 
because it was in stock in the lab. In a sterile 1.5 mL centrifuge tube, 300 μL Midiprep DNA, 34 
μL 10X Buffer D, 3 μL 100X BSA, and 3 μL BstXI were added. The reaction was placed in a 
37
o
C water bath for four hours. After four hours, an additional 4 µL of BstXI was added to the 
reaction. The digestion was continued at 37
o
C overnight. A 0.8% agarose gel was made to run a 
sample containing: 1 μL digestion product, 4 μL distilled water, and 1 μL 6X dye. The gel 
confirmed complete linearization of the plasmid DNA.  Once confirmed, the sample was placed 
in the 65
o
C water bath to stop the digestion. The digested DNA was stored at 4
o
C until the 
phenol:chloroform extraction and ethanol precipitation could be performed.  
 
Concentration of Linearized DNA  
 To concentrate the linearized DNA to sufficient amounts for electroporation, a phenol: 
chloroform extraction was performed. The phenol: chloroform solvent was prepared as described 
in Appendix A.  First, 350 μL phenol:chloroform solvent was added to the linearized DNA in a 
microfuge tube. The tube was vortexed and then centrifuged at 13,000 x g for 2 minutes. Second, 
300 μL of the upper aqueous phase was extracted and transferred to a new, sterile microfuge 
tube. After transfer, 30 μL of 7.5 M sodium acetate and 750 μL 100% ethanol were added to the 
sample. The sample was either incubated on ice for two hours or stored at -20 
o
C overnight to 
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precipitate the DNA. After this time, the microfuge tube was centrifuged for 10 minutes at 
14,000 X g at 4
o
C. The supernatant was discarded, and the DNA pellet was resuspended in 1 mL 
80% ethanol. The microfuge tube was centrifuged again for 10 minutes at 14,000 X g at 4
o
C. The 
supernatant was discarded. The tube was inverted to dry for 30 minutes. For best results, the tube 
was placed in a SpeedVac Concentrator (Thermo Electron Corporation) for 15 minutes. The 
DNA was resuspended in sterile, distilled water, 5 to 20 μL for best results. The concentration of 
DNA was determined using the NanoDrop.  A 20:1 diluted sample was used to test the 
concentration so as not to waste any DNA for electroporation. The linearized DNA, ready for 
electroporation, was stored at -20 
o
C.  
 
Yeast Harvest for Electroporation 
 With linearized DNA prepared for transformation, competent yeast cells were grown. An 
overnight 5 mL culture of Pichia pastoris strain X33 was grown at 30
o
C and 250 rpm in YPD 
(yeast, peptone, dextrose) media. (See Appendix B for recipe) Next, 100 μL of the yeast culture 
was inoculated into 50 mL YPD media and grown overnight at 30
o
C and 250 rpm until reaching 
the recommended OD600 of 1.3-1.5. The density was testing using a spectrophotometer against a 
blank of YPD media. The optimal density was reached after approximately 13.5 hours. The yeast 
cells were harvested at 4
o
C in a Sorvall
®
 RC-5B super speed centrifuge (Fisher Scientific) at 
1,500 X g for 5 minutes. The cells were washed with 50 mL ice cold, sterile distilled water and 
centrifuged at the same rate and time. The cells were then washed with 10 mL ice cold, sterile 
distilled water and centrifuged at the same rate and time after which the cells were washed with 
10 mL ice cold, sterile 1 M sorbitol and centrifuged at the same rate and time. The cells were 
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then resuspended in 1 mL ice cold, sterile 1 M sorbitol. The yeast cells were stored on ice until 
subsequent use for electroporation.  
Electroporation of PGT 4 into Yeast 
 Following the Invitrogen EasySelect
TM
 Pichia manual, a 0.2 cm micro pulser cuvette 
(Bio-Rad) and the sample of concentrated, linearized DNA were incubated on ice for 5 minutes. 
From the yeast harvest, 80 μL of yeast cells were transferred to the linearized DNA sample and 
incubated on ice for 5 minutes. The mixture was then added to the cold electroporation cuvette 
and incubated on ice an additional 5 minutes. The cuvette was placed in a micropulser and 
pulsed once at 1.5 kV. Immediately after the pulse, 1 mL ice cold 1M sorbitol was added to the 
cuvette. The contents of the cuvette were transferred to a sterile 15 mL tube and incubated at 
30
o
C for one hour without shaking after which the transformants were spread evenly over 
YPDSzeocin (100mg/L) plates (See Appendix B for recipe) in 25, 50, 100, and 200 μL aliquots. 
The plates were incubated at 28 
o
C for 2-3 days until colonies were observed. After initial 
growth, the plates were stored at 4 
o
C.  
 
PCR Screen of Yeast Transformants 
 To confirm transformation of PGT 4 into the yeast genome, a PCR screen using AOX1 
primers was conducted. Colonies were chosen at random to test. Each chosen colony was 
inoculated into 10 μL sterile, distilled water in a PCR tube. To isolate the DNA from the yeast 
cells, 5 μL of 5U/ μL lyticase was added to each PCR tube. The samples were incubated at 30
o
C 
for 10 minutes and then at -80
o
C for 10 minutes. The cell lysates were then thawed and used as 
template for PCR. A negative control of empty pPICZA vector and a positive control of 
Miniprep plasmid of PGT 4 in pPICZA were also used as control templates. In each PCR 
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reaction the following was added: 5 μL 2X PCR Master Mix (See Appendix B for recipe), 0.5 
μL 10 mM 5’ AOX1 primer, 0.5 μL 10 mM 3’ AOX1 primer, 3 μL sterile water, and 1 μL DNA 
template. The PCR was run in a thermocycler with the following protocol (Table 8).  
Table 8. Temperature Protocol for PCR with AOX1 primers 
Step Temperature (
o
C) Time 
1 95 5 minutes 
2 95 1 minute 
3 54 1 minute 
4 72 1 minute 
5 72 7 minutes  
 
 To confirm insertion, the 10 μL PCR products were loaded onto a 0.8% agarose gel and 
run for 1 hour at 100 volts. The gel was visualized to verify positive bands corresponding to the 
1467 bp PGT 4 sequence plus 300 bp of AOX1 priming sequence. Colonies found to be 
positively transformed were freshly streaked on YPDSzeocin (100mg/L) plates. Also, cultures of 
each positive colony were grown overnight in YPDSzeocin (100mg/L) media, saved in 50% 
glycerol, and stored at -80
o
C.  
Test Inductions for Expression of PGT 4  
  From each of the freshly streaked plates of positively transformed colonies, a single 
colony was inoculated into 25 mL BMGY (See Appendix B for recipe) in a 250 mL baffled 
flask. The culture was grown overnight at 30
o
C and 250 rpm to generate biomass. The culture 
was grown until it reached an OD600 of 2-6 (approximately 22 hours) (Invitrogen). The yeast 
cells were harvested by centrifugation in a Sorvall
®
 RC-5B at 4
o
C for 5 minutes at 3,000 X g. 
The cells were resuspended in 30 mL BMMY (See Appendix B for recipe) and centrifuged again 
for 5 minutes at 3,000 X g. The cells were resuspended in 50 mL BMMY and transferred to 
sterile 500 mL baffled flasks. Additional aliquots of BMMY were added to the cultures to reach 
30 X 
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an OD600 of 1. The flasks were covered with two layers of cheesecloth to allow aeration for 
proper culture growth. The flasks were shaken at 30
o
C and 250 rpm. Every 24 hours, 100% 
methanol was added to the cultures to a final concentration of 0.5% methanol to maintain 
induction. Samples were taken out every six hours on the first day and every 12 hours on days 2-
4. A 1 mL sample was taken from each culture at the following time points (hours): 0, 6, 
12,24,36,48,60,72,84, and 96. Each 1 mL sample was centrifuged at 13,000 X g for 3 minutes. 
The supernatant was discarded, and the cell pellet was stored at -80
o
C until SDS-PAGE analysis.  
 
Preparation of Samples for SDS-PAGE Analysis 
  Cell pellets were thawed on ice. One hundred μL Breaking Buffer with 1% PMSF (See 
Appendix B for recipe.) and an equal amount of acid-washed glass beads were added to each 
sample. The samples were vortexed for thirty seconds and placed on ice for thirty seconds for 
eight cycles. After lysing the cells, samples were centrifuged for 10 minutes at 14,000 x g at 4
o
C.  
The supernatant was transferred to a new, sterile centrifuge tube. Concentrations of protein 
within the samples were measured with the Nano Drop. Fifteen microliters was prepared for each 
well containing 5 μL loading dye and 15 μL mixture of sample and distilled water.  To 
accurately analyze the amount of activity at different time intervals, an equal amount of protein 
from each sample was loaded onto the protein gel. The amount of protein in15 μL of the sample 
with the lowest concentration was calculated and the same amount of protein was loaded from 
each sample. Distilled water was used to dilute the more concentrated samples to 15 μL. The 
samples were boiled for ten minutes and centrifuged for 1 minute at 13,000 x g before loading. 
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SDS-PAGE Electrophoresis 
 A protein electrophoresis cell from BioRad was used. Two glass plates were secured in 
clamps.  Ten percent separating gel and fifteen percent stacking gel solutions were mixed in 
separate beakers following recipe in Appendix C.  The 10% separating gel was poured by pipet 
in between the glass plates until reaching 2 cm from the top and allowed to solidify for 25 
minutes. To level off the top of the separating gel, 400 μL water-saturated butanol was poured 
between the plates. After five minutes, the butanol was lifted off the gel using Whatman paper. 
The 15% stacking gel was poured by pipet to the top of the glass plates, eliminating any bubbles 
between the plates. A comb was inserted in between the plates and allowed to solidify for 25 
minutes. The plates were placed within the electrophoresis cell, and 1 X TANK Buffer was 
added to the middle and outer compartments (See Appendix B for recipe). The wells were loaded 
with the 20 μL prepared samples using flat pipet tips. The cell was run for 15 minutes at 85V and 
1.5 hours at 100V.   
Staining and Destaining of Protein Gels 
 Protein gels were stained with Coomassie® Brilliant Blue R250 and destained with gel 
destaining solution (See Appendix B for recipes). Staining solution was added to protein gels in a 
dish and heated in microwave for 10 seconds, not allowing the solution to boil. The gels were 
then shaken for 15 minutes. The solution was decanted, and the protein gels were rinsed with 
distilled water. Destaining solution was added to the gels, and they were heated in the microwave 
for 10 seconds. Gels were shaken until desirable background was achieved.  
 Protein gels were also silver stained according to the manufacturer’s instructions in the 
Bio-Rad Silver Stain Kit. Developed gels were photographed and archived. 
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Electro-blotting of SDS-PAGE 
 While the protein gel was running, pieces of Whatman paper (3MM CHR) and 
nitrocellulose membrane were cut to the size of the protein gel. The nitrocellulose membranes 
were moistened in distilled water for 5 minutes. Electro-blotting cassettes, porous pads, and filter 
were moistened in a glass dish in 1 X Transfer Buffer (See Appendix B for recipe). The electro-
blotting cassettes were assembled as follows without air bubbles in between the layers: anode 
side, porous pad, filter paper, protein gel, nitrocellulose membrane, filter paper, porous pad, and 
cathode side. The cassettes were fastened and loaded into the cell. A stirrer bar gently stirred the 
buffer in the cell when connected to a voltmeter at 65V for 1 hour.  
Western Blot Analysis 
 After electro blotting, the protein gel was placed in a tray of Coomasie BrilliantBlue 
G250 and gently shaken overnight to be destained later (See Appendix B for Coomasie staining 
and destaining solutions). The nitrocellulose membrane was immediately placed into a tray of 
blocking solution (Appendix B) and gently shaken for 2 hours. The blocking solution was poured 
off, and the membrane was washed by gently shaking with 25 mL TBS with 0.02% sodium azide 
for10 minutes. The wash was poured off, and the primary antibody, a monoclonal antibody c-
myc from mouse, was added in a 30 mL 1:2500 solution of TBS with 0.02% sodium azide and 
gently shaken for 2 hours. The primary antibody solution was poured off, and the membrane was 
washed three times for 10 minutes each with 50 mL TBS without sodium azide. The membrane 
was transferred to a new tray, and the secondary antibody, a goat, anti-mouse immunoglobulin G 
conjugate to alkaline phosphatase (IgG-AP), was added in a 30 mL 1:10000 solution of TBS 
without sodium azide and gently shaken for 2 hours. The secondary antibody was poured off and 
the membrane was washed as before. The membrane was then added to a tray of developing 
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solution (See Appendix B for recipe) for up to 1 minute until bands were visible. The membrane 
was immediately transferred to the stop buffer (50 mL 1X TBS, 200 µL 0.5M EDTA, pH 8). 
After 5 minutes in the stop buffer, the membrane was dried on a paper towel. All Western blots 
were scanned and originals archived into a lab notebook.   
Scale-Up Expression of PGT 4  
 Western blot analysis found optimum post-induction times for PGT 4. Twelve hours 
post-induction was chosen due to darkness of band on Western blot and convenience of 
experiment timing for purification. A scale-up of expression was conducted by growing a 100 
mL yeast culture to induce with methanol for protein production. A fresh yeast colony was 
inoculated into 25 mL BMGY for 18 hours at 37
o
C and 250 rpm until OD600 of 2-6.  A 1 mL 
aliquot of the 25 mL culture was inoculated into 50 mL of BMGY and grown 18 more hours at 
37
o
C and 250 rpm to an OD600 of 2-6. The cells were harvested by centrifugation at 3,000xg and 
4
o
C for 5 minutes. The cells were washed with 20 mL BMMY, containing methanol, and 
centrifuged at 3,000xg and 4
o
C for 5 minutes. The cells were resuspended in BMMY, containing 
methanol, to an OD600 of 1.  The yeast culture was split into 2-50 mL centrifuge tubes. The cells 
were harvested by centrifugation at 3,000xg and 4
o
C for 5 minutes. The cell pellets were saved at 
-80
 o
C until enzyme purification and assay.  
Purification and Concentration of PGT 4 
 Cell pellets were thawed on ice. To each pellet, 3 mL of Breaking Buffer with 1 mM 
PMSF was added (See Appendix A for recipe). The suspended pellet and buffer (6 mL) was 
poured into a French press (Thermo Electron Corporation). The cells were lysed three times at 
2000 psi. The cell lysate was centrifuged at 13,000xg and 4
 o
C for 20 minutes. The supernatant 
was decanted into a new test tube and stored on ice, and the cell pellet was discarded.   
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A PD-10 column was equilibrated with 25 mL of Column Buffer (See Appendix A for 
recipe).  A 2.5 mL aliquot of cell lysate was applied to the equilibrated PD-10 column to remove 
any salt from the protein. The flow through was discarded, and 3.5 mL Column Buffer was 
applied to the column to elute the protein. The flow through was collected in a 50 mL centrifuge 
tube and labeled PD-10 elution. Another 2.5 mL aliquot of cell lysate was desalted in the same 
manner. The PD-10 was re-equilibrated with 25 mL Column Buffer to restore the column for 
further use.   
 The protein was further purified using an immobilized metal affinity chromatography 
(IMAC) column from TALON™ Resins. All purification techniques were done at 4 
o 
C to 
maintain stability of the enzyme. The histidine tag on the recombinant protein allows for 
purification through metal affinity by binding the protein to the column and eluting it with 
imidazole. The 4 mL bed IMAC column was equilibrated with 40 mL Column Buffer.  The PD-
10 elution was applied slowly to the column. The flow through was collected in 2 mL centrifuge 
tubes in 1 mL fractions. The IMAC column was washed with column buffer until all non-bound 
proteins had been removed, leaving only tagged protein. The wash was collected in 2 mL 
centrifuge tubes in 2 mL fractions. When protein concentration was below 0.1 mg/mL, Column 
Buffer with 150 mM imidazole was applied to the column to elute the tagged protein. Ten each 2 
mL fractions were taken and tested for protein concentration using the NanoDrop at 280 nm.  
Four 2 mL elution fractions with the highest concentration of protein were added to a Amicon® 
Ultra-15 and centrifuged at 4,000xg and 4
o
C for 10 minutes. Centrifugation was continued until 
the sample was concentrated to 500 µL. To remove imidazole from the purified protein, the 
concentrated sample was resuspended to a final volume of 2 mL with 50 mM phosphate buffer 
with 14 mM βME (See Appendix A for recipe) and centrifuged again at the same rate and time 
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until concentrated to 500 µL. The concentrated sample was resuspended to a final volume of 2 
mL with 50 mM phosphate buffer with 14 mM βME and stored on ice for enzyme assay. After 
enzyme assay, the enzyme was stored at 4
o
C for SDS-PAGE and Western blot analysis. The 
IMAC column was equilibrated with 20 mL MES buffer, 20 mL milliQ water, and 25 mL 20% 
ethanol with 0.1% sodium azide for storage and reuse. 
Preparation of 
14
C-UDP-glucose and Flavonoid Substrates for Enzyme Assay 
 To test for enzyme activity, 
14
C-UDP-glucose was used as the substrate donor. A working 
solution of 
14
C-UDP-glucose was prepared by mixing 50 µL 
14
C-UDP-glucose (261 mCi/ mmol) 
with 950 µL 50 mM phosphate buffer to reach 20000 cpm/10µL. Various flavonoids were used 
as the substrate acceptors (Table 9). A working solution of each flavonoid substrate was 
dissolved into 100% ethylene glycol monomethylether to a concentration of 50nmoles/5µL and 
stored at -20
 o
C.  
Table 9. Flavonoid Substrates Screened with PGT 4 for Activity  
Flavonoid subclass Substrate Name Substrate Structure 
Flavanones 
Naringenin 
 
Hesperitin 
 
Eriodictyol 
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Isosakuranetin 
 
Flavones 
Apigenin 
 
Luteolin 
 
Diosmetin 
 
Scutellerin 
 
Flavonols Kaempferol 
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Quercetin 
 
Fisetin 
 
Gossypetin 
 
4’-methoxyflavonol 
 
 
 
Isoflavone 
4’-acetoxy-7-hydroxy-6-
methoxy-isoflavone 
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Screening of PGT 4 for Flavonoid Glucosyltransferase Activity 
 A total of 14 flavonoids were used as potential acceptor substrates to screen for GT 
activity with PGT 4. Each test reaction was performed in duplicate with each flavonoid substrate. 
A negative control using enzyme denatured with HCl were also performed in duplicate with each 
flavonoid substrate. This negative control served as a background reading of activity with each 
substrate. The test results were corrected against these background readings to verify positive 
activity. A second negative control was conducted with quercetin using denatured PGT 4 that 
had been boiled for ten minutes. A positive control using young grapefruit leaf extract as the GT 
enzyme source was performed with quercetin. A second positive control combining young 
grapefruit leaf extract and PGT 4 was performed to test for possible inhibiting effects of rPGT 4 
on glucose incorporation.  
 The screening assay was adapted from McIntosh et al. (1990). For each test reaction the 
following contents were added in respective order: 50 µL 50 mM phosphate buffer with 14 mM 
βME, 5 µL flavonoid substrate (50 nmol), 10 µL 
14
C-UDP-glucose working solution (20,000 
cpm), and 10 µL purified enzyme. For each negative control reaction, 15 µL 6M HCl was added 
before the enzyme. The second negative control used 10 µL boiled enzyme. For the first positive 
control, 60 µL young grapefruit leaf extract, suspended in 50 mM phosphate buffer with 14 mM 
βME, 5 µL quercetin, and 10 µL  
14
C-UDP-glucose working solution was added to a reaction 
tube. The young grapefruit leaf extract was prepared by crushing a young grapefruit leaf with 
mortar and pestle in 2 mL 50 mM phosphate buffer with 14 mM βME and pH 7.5. For the 
second positive control, 50 µL young grapefruit leaf extract, 5 µL quercetin, 10 µL 
14
C-UDP-
glucose, and 10 µL purified enzyme was loaded into a reaction tube. Each control was performed 
in duplicate.  
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 Each reaction was incubated for 5 minutes at 37
 o
C.  After 5 minutes, 15 µL 6M HCl was 
added and vortexed for 10 seconds to stop the reaction. To separate any radiolabeled flavonoid 
glucosides from unincorporated 
14
C-UDP-glucose, 250 µL ethyl acetate was added to the 
reaction tube, vortexed for 10 seconds, and separated into organic and aqueous phases. A volume 
of 100 µL was pipeted from the top organic phase and added to 2 mL scintillation fluid. The 
amount of radiolabeled 
14
C-UDP-glucose transferred to flavonoid substrates was analyzed using 
a Beckman LS 6500 scintillation counter and counts corrected to determine cpm in 250 µL of 
ethyl acetate.   
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RESULTS AND DISCUSSION 
 
Confirmation of PGT 4 for Transformation 
 PGT 4 had been previously tested for flavonoid GT activity in E.coli. Limited substrates 
were used and little activity was found. One challenge that arose was the presence of inclusion 
bodies within the prokaryotic system. The inclusion bodies were found to store the induced 
protein, and substantial soluble protein was not present for analysis. Thus, PGT 4 was to be 
transformed into a eukaryotic system, Pichia pastoris, in order to obtain more soluble protein for 
analysis.  
 PGT 4 glycerol stocks from Josephat Asaigo were used to confirm the sequence of PGT 4 
before insertion in pPICZ A and transformation into yeast. Primers were designed based on 
previous sequencing results. A previously compiled Bioedit sequence of PGT 4 was obtained 
from Dr. Daniel Owens. Clone specific primers were designed based on the information from 
this sequence. See Table 1 for the sequences of primers CSP 144 F and CSP 145 R. Cultures of 
the glycerol stocks were made in LB media, and MiniPreps were conducted to isolate DNA 
plasmid. The newly designed primers were used in a polymerase chain reaction with plasmid 
DNA as template and with a TM of 64 
o 
C to confirm the presence of the full length PGT 4 
sequence within the glycerol stocks. However, PCR product was not found (Figure 9). PCR was 
repeated with several different stocks with no resulting band at the expected size of full-length 
PGT 4, 1467 base pairs.  
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Figure 9. PCR of glycerol stocks of PGT 4. Lane M is 1 kb ladder. Lanes 2-6 are PCR product 
of 5 different PGT 4 glycerol stocks. No PCR product at 1467 bp was found.  
 
 PCR was repeated with a lower TM , 59 
o 
C. It was hypothesized that the primers could not 
anneal properly to the template because their sequences were not completely conserved to that of 
PGT 4.  The agarose gel of the second PCR reaction had identical results. It was hypothesized 
that the full length was not present within the stocks. Thus, DNA from MiniPreps of several 
different glycerol stocks was sent to UTK for sequencing. The results showed that no glycerol 
stock contained the full length sequence; however, each one had a partial PGT 4 clone.  
Reconstruction of PGT 4  
 Before transformation into yeast could occur, full-length PGT 4 had to be reconstructed. 
Two partial clones were found, that when digested and ligated together, could reconstruct the full 
length PGT 4 sequence. The partial clones, 181.2A and 155.1A, were archived by a previous 
researcher, Christy Strong.  After receiving the sequencing results of these 2 partial clones, a 
cloning strategy was designed. The single internal restriction site within the overlapping region 
of the 2 partial clones that cut PGT 4’s sequence only once was EcoRI. However, both partial 
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clones were saved within the pCR
®
 4-TOPO
®
 vector, whose multiple cloning site contains 
multiple sites for EcoRI (See Figure 4). With EcoRI sites on either side of the partial clone 
inserts, the desired pieces of the clones could not be directly digested and ligated.  A new 
strategy was designed.  
 The partial clone sequences could be amplified out of the pCR
®
 4-TOPO
®
 vector by 
PCR. To PCR amplify, more clone specific primers were made (Figure 10). To be transformed 
into yeast, PGT 4 was to first be cloned into the pPICZ A cloning vector.  Thus, primers to 
amplify the partial clones were designed with this in mind. The 5’ and 3’ end restriction enzyme 
sites were chosen to be Kpn I and Not I to allow for directional cloning into the pPICZA vector 
(Figure 11). The 1100 bp piece of Clone 181.2A and 300 bp piece of Clone 155.1A were to be 
PCR amplified out of the pCR
®
 4-TOPO
®
 vector and ligated into the pCD1 cloning vector one at 
a time (Figure 12).  
 
Figure 10. Reconstruction of PGT 4. This diagram shows the cloning strategy of the 2 partial 
clones to successfully reconstruct PGT 4.  
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Figure 11. Vector Map of pPICZ A. Restriction enzymes Kpn I and Not I were chosen for the 5’ 
and 3’ primer restriction enzyme sites, respectively. The map shows these enzymes directionally 
in its multiple cloning site (Invitrogen). 
 
 
 
Figure 12.  This pCD1 vector map shows the restriction cloning sites directionally (5’ to 3’). 
This vector was a gift from Brenda Winkel of Virginia Tech. The restriction enzymes chosen 
digest pCD1 a single time. The partial clones were inserted directionally one at a time.   
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PCR Amplification of 181.2A piece 
 
 The strategy to PCR amplify the partial clones out of the pCR
®
 4-TOPO
® 
vector and 
directionally clone the pieces into the pCD1 vector was successful. To reconstruct PGT 4, Clone 
181.2A was amplified by PCR with clone specific primers, CSP 144F and CSP 149R. See Table 
2 for details. Figure 13 shows the 1100 bp piece of Clone 181.2A that was PCR amplified from 
MiniPrep DNA of Clone 181.2A.   
 
 
 
Figure 13. PCR Amplification of 181.2A piece. Lane M is the 1 kb ladder. Lane 1 is pCD1 
vector MiniPrep DNA. Lanes 2-5 are PCR products with CSP 144F and CSP 149R. The band 
around 1100 bp suggests the desired 181.2A piece.  
 
 
 
 The 181.2A bands at around 1100 bp were extracted and gel purified. Multiple bands 
were excised and purified to obtain a good DNA concentration for digestion. The purified DNA 
was used for digestion with KpnI and EcoRI.  The pCD1 vector was also digested with Kpn I and 
EcoRI in order for the insert and vector to be ligated together (Figure 14).  
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Figure 14.  Digestion of 181.2A piece and pCD1 vector. M represents 1 kb ladder. A. Lanes 1-
3 are 181.2A digestion with KpnI and EcoRI.  B. Lanes 1-4 are pCD1 vector digested with KpnI 
and EcoRI. All wells were loaded with 15 µL from digestion and 3 µL 6x loading dye. Bands 
were excised and gel purified for ligation.  
 
Ligation and Transformation of 181.2A into pCD1 
 The digested 181.2A piece bands and the digested pCD1 bands were extracted and gel 
purified. The digested DNA of the insert and the vector were ligated together. The ligated 
product was transformed into OneShot
® 
Top 10 Cells. Colonies were grown on selective LB 
plates with ampicillin (100 mg/L). Four transformant colonies grew overnight on the plates at 
37
o
C.  A PCR screening was conducted with CSP 144F and CSP 149R to verify the presence of 
the 181.2A piece within the pCD1 vector. The ligation ratio of 3:1 insert:vector resulted in 
colonies which successfully included the 181.2A insert. Two colonies showed a positive band at 
1100 bp, suggesting the 181.2A piece was successfully ligated in the vector (Figure 15).  
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Figure 15. PCR Screen for Confirmation of 181.2A Ligation.  M represents 1 kb ladder. 
Lanes 1-4 are PCR product from transformed colonies. The band around 1100 bp indicates the 
presence of the 181.2A piece within pCD1.  
 
The colonies containing the insert, Colonies 3 and 4 were inoculated into LB media with 
ampicillin (100 mg/L). DNA plasmid was isolated to send for sequencing. Once the sequence 
was confirmed, more DNA plasmid was isolated to insert the second partial clone, 155.1A.  
PCR Amplification of 155.1A 
 Clone specific primers were designed to amplify 155.1A out of the pCR
®
 4-TOPO
®
 
vector. CSP 150F and CSP 151R were used in the PCR reaction (See Table 2 for details).  The 
PCR products showed a band around 300-400 bp, the desired size of the 155.1A piece (Figure 
16).  
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Figure 16. PCR Amplification of 155.1A piece. M is 1 kb ladder. Lanes 1-5 are PCR product 
of 155.1A piece. Bands were excised, gel purified, digested with EcoRI and NotI and ligated into 
pCD1.  
 These five bands were excised and gel purified for digestion. To reconstruct PGT 4 
directionally, the pCD1 vector with the 181.2A insert and the 155.1A piece were both digested 
with EcoRI and NotI.  Figure 17 shows an agarose gel of a digestion of pCD1 + 181.2A piece 
and of 155.1A piece. The 155.1A piece bands were extracted and gel purified. The pCD1 + 
181.2A piece digestion was not successful and was repeated, Figure 18. The bands were 
extracted and gel purified for ligation.  
 
Figure 17. Digestion of pCD1 vector and 155.1A piece. M is 1 kb ladder. Lanes 1-2 are pCD1 
digested with EcoRI and NotI. Lanes 3-5 are 155.1A piece digested with EcoRI and NotI.  
Digestion of pCD1 was repeated for proper bands. Bands from Lanes 3-5 were used for ligation.  
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Figure 18. Repeated digestion of pCD1. M is 1 kb ladder. Lanes 1-3 are pCD1 digested with 
EcoRI and NotI. Bands were excised and gel purified for ligation.   
 
Ligation and Transformation of 155.1A piece into pCD1 + 181.2A piece 
 The DNA from gel purification was used to set up a ligation. The ligation product was 
transformed into OneShot
® 
Top 10 Cells. Colonies were grown on selective LB plates with 
ampicillin (100 mg/L). Nine transformant colonies grew overnight on the plates at 37
o
C.  A PCR 
screening was conducted with CSP 144F and CSP 151R to verify the presence of the 155.1A 
piece within the pCD1 vector. One colony showed a positive band at around 1500 bp, suggesting 
the 155.1A piece was successfully ligated in the vector. This band suggests the full length 
reconstruction of PGT 4 (Figure 19).  
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Figure 19. PCR Confirmation of PGT 4 Reconstruction. M is 1 kb ladder. Lanes 1-11 are 
PCR product from each respective colony found on selective plates after transformation. Colony 
4 shows a band at 1500 bp suggesting presence of full length PGT in plasmid DNA.  
 
 The colony containing full length PGT 4, Colony 5, was inoculated into LB media with 
ampicillin (100 mg/L). DNA plasmid was isolated to send for sequencing. The sequencing 
results confirmed the successful reconstruction of PGT 4 (Figure 20).  
 
            ....|....| ....|....| ....|....| ....|....| ....|....|  
                     510        520        530        540        550         
PGT 4        ---------- ---------- ATGGCATCCG AAGCCAGCCA GGTTCACTTT  
sequencing   ACAGCCCAGA TCTGGGTACC ATGGCATCCG AAGCCAGCCA GGTTCACTTT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     560        570        580        590        600         
PGT 4        CTCTTGCTTC CTTACTTGGC TCCAGGCCAC TTGATTCCCA TGTTTGACAT  
sequencing   CTCTTGCTTC CTTACTTGGC TCCAGGCCAC TTGATTCCCA TGTTTGACAT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     610        620        630        640        650         
PGT 4        TGCTAGATTG CTTGCACAGC ATGGAGCTAT TGTTACTATT GTCACCACCC  
sequencing   TGCTAGATTG CTTGCACAGC ATGGAGCTAT TGTTACTATT GTCACCACCC  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     660        670        680        690        700         
PGT 4        CAGTTAATGT GGCAAGGTTC AAAACAGTGA TTGCTCGTGC AATAAAATCC  
sequencing   CAGTTAATGT GGCAAGGTTC AAAACAGTGA TTGCTCGTGC AATAAAATCC  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     710        720        730        740        750         
PGT 4        GGCCTACAAA TCCGACTAAT TGAGATCCAG TTTCCTTGGC AAGAAGCAGG  
sequencing   GGCCTACAAA TCCGACTAAT TGAGATCCAG TTTCCTTGGC AAGAAGCAGG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     760        770        780        790        800         
PGT 4        AATACCTGAA GGTTGTGAGA ATTGTGACTT GCTTCCTACA ACAGACTTTG  
sequencing   AATACCTGAA GGTTGTGAGA ATTGTGACTT GCTTCCTACA ACAGACTTTG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     810        820        830        840        850         
PGT 4        CAAGGTTCAT GAAGTCGCTT CACATGCTTC AACAGCCTTT TGAAAATTTG  
sequencing   CAAGGTTCAT GAAGTCGCTT CACATGCTTC AACAGCCTTT TGAAAATTTG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     860        870        880        890        900         
PGT 4        TTCAAAGAGA AAACTCTTAA GCCCTGCTGC ATAATCTCTG ACATGTGTTT  
sequencing   TTCAAAGAGA AAACTCTTAA GCCCTGCTGC ATAATCTCTG ACATGTGTTT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     910        920        930        940        950         
PGT 4        TCCTTGGACG GTGGATACAG CTGCCAAGTT CAATGTTCCA AGGATTATTT  
sequencing   TCCTTGGACG GTGGATACAG CTGCCAAGTT CAATGTTCCA AGGATTATTT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     960        970        980        990        1000        
PGT 4        TCCATGGATT TTCTTGCTTC TGTCTCTTCT GTCATCACCT CTTGGG-TGT  
sequencing   TCCATGGATT TTCTTGCTTC TGTCTCTTCT GTCATCACCT CTTGGGGTGT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1010       1020       1030       1040       1050        
PGT 4        TTCAAAGGTT CACGAGAATG TTACTTCTGA TTCAGAGTAC TTTAATATAC  
sequencing   TTCAAAGGTT CACGAGAATG TTACTTCTGA TTCAGAGTAC TTTAATATAC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1060       1070       1080       1090       1100        
PGT 4        CAAGTATTGA TATTATCACA CCCTGCAGTC GGAGGGTTCT TAACGCATTG  
sequencing   CAAGTATTGA TATTATCACA CCCTGCAGTC GGAGGGTTCT TAACGCATTG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1110       1120       1130       1140       1150        
PGT 4        CGGCTGGAAT TCATCTCTGG AAGGGATATC AGCTGGGGTT CAAATGCTTA  
sequencing   CGGCTGGAAT TCATCTCTGG AAGGGATATC AGCTGGGGTT CAAATGCTTA  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1160       1170       1180       1190       1200        
PGT 4        CATGGCCACT CTTTGCAGAC CAATTTTGCA ATGAGAAGTT GATTGTGAAT  
sequencing   CATGGCCACT CTTTGCAGAC CAATTTTGCA ATGAGAAGTT GATTGTGAAT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1210       1220       1230       1240       1250        
PGT 4        GTTTTAAGGA TTGGTGTGAG TGTTGGAGTG GAAGTTCCAA TGAATTTTGG  
sequencing   GTTTTAAGGA TTGGTGTGAG TGTTGGAGTG GAAGTTCCAA TGAATTTTGG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1260       1270       1280       1290       1300        
PGT 4        AGAAGAAGAG AAGATTGGAG TATTGGTGAA TAAGGAAAAT GTCAAAACGG  
sequencing   AGAAGAAGAG AAGATTGGAG TATTGGTGAA TAAGGAAAAT GTCAAAACGG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1310       1320       1330       1340       1350        
PGT 4        CTATAAACAT ACTGATGGAT GATGGAGAGG AAAGAAATGC GAGAAGAAGT  
sequencing   CTATAAACAT ACTGATGGAT GATGGAGAGG AAAGAAATGC GAGAAGAAGT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1360       1370       1380       1390       1400        
PGT 4        GCCAGAGAGT TTGGAGAGTT GGCTAAAAGA GCTATAGATG AAGGTGGATC  
sequencing   GCCAGAGAGT TTGGAGAGTT GGCTAAAAGA GCTATAGATG AAGGTGGATC  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1410       1420       1430       1440       1450        
PGT 4        TTCCTATAAC AACGTCGAAT TATTTATGCA AGATATCATG CAACAGCCGA  
sequencing   TTCCTATAAC AACGTCGAAT TATTTATGCA AGATATCATG CAACAGCCGA  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1460       1470       1480       1490       1500        
PGT 4        GCTCAGAAGT GATTTAA--- ---------- ---------- ----------  
sequencing   GCTCAGAAGC GATTGCGGCC GCACTCGAGC ACCACCACCA CCACCACTGA  
 
Figure 20. Sequencing Results Confirming Reconstruction of Full-Length PGT 4 
 
Cloning into pPICZ A 
 When designing primers to amplify the partial clones, restriction enzymes were chosen 
that existed directionally within the pPICZ A multiple cloning site (Figure 11). To clone PGT 4 
into the pPICZ A vector, full-length PGT 4 in pCD1 and empty pPICZ A vector were both 
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digested with KpnI and NotI.  Figure 21 shows both digestions. The bands were excised and gel 
purified. The purified DNA was used for a ligation.   
  
  
Figure 21. Digestion of pPICZ A vector and PGT 4 in pCD1. M is 1 kb ladder. Lanes 1-2 are 
pPICZ A vector digested with KpnI and NotI.  Lanes 3-5 are PGT 4 in pCD1 digested with KpnI 
and NotI. Bands from Lanes 1-2 and bands at 1500 bp from Lanes 3-5 were excised, gel purified, 
and used for ligation.  
 
 The ligation product was transformed into OneShot
® 
Top 10 Cells. Colonies were grown 
on selective LB plates with zeocin (25 mg/L). Twelve transformant colonies grew overnight on 
the plates at 37
o
C.  A PCR screening was conducted with CSP 144F and CSP 151R to verify the 
presence of the PGT 4 within the pPICZ A vector. Five colonies showed a positive band at 
around 1500 bp, suggesting PGT 4 was successfully ligated in the pPICZ A vector (Figure 22).  
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Figure 22. PCR Screening of Transformed ligated pPICZ A and PGT 4. M is 1 kb ladder. 
Lanes 1-13 are PCR product from respective colonies. Lane 13 is a positive control. Lane 14 is a 
negative control. Colonies 2,3, 8, 9 and 10 showed bands at 1500 bp suggesting presence of PGT 
4 within plasmid DNA.  
 
 The colonies containing full length PGT 4, Colonies 2,3,8,9, and 10, were inoculated into 
LB media with zeocin (25 mg/L). The isolated DNA plasmid was sent for sequencing. The 
sequencing results confirmed the successful insertion of PGT 4 into the pPICZ A vector (Figure 
23).  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      60         70         80         90        100             
PGT 4        ---------- ---------- ---------- ---------- ----ATGGCA  
5' C5        ACGAGGAATT CACGTGGCCC AGCCGGCCGT CTCGGATCGG TACCATGGCA  
3' C5        ---------- ---------- ---------- ---------- ----------  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     110        120        130        140        150         
PGT 4        TCCGAAGCCA GCCAGGTTCA CTTTCTCTTG CTTCCTTACT TGGCTCCAGG  
5' C5        TCCGAAGCCA GCCAGGTTCA CTTTCTCTTG CTTCCTTACT TGGCTCCAGG  
3' C5        ---------- ---------- ---------- ---------- ----------  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     160        170        180        190        200         
PGT 4        CCACTTGATT CCCATGTTTG ACATTGCTAG ATTGCTTGCA CAGCATGGAG  
5' C5        CCACTTGATT CCCATGTTTG ACATTGCTAG ATTGCTTGCA CAGCATGGAG  
3' C5        ---------- ---------- ---------- ---------- ----------  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     210        220        230        240        250         
PGT 4        CTATTGTTAC TATTGTCACC ACCCCAGTTA ATGTGGCAAG GTTCAAAACA  
5' C5        CTATTGTTAC TATTGTCACC ACCCCAGTTA ATGTGGCAAG GTTCAAAACA  
3' C5        ---------- ---------- ---------- ---------- ----------  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     260        270        280        290        300         
PGT 4        GTGATTGCTC GTGCAATAAA ATCCGGCCTA CAAATCCGAC TAATTGAGAT  
5' C5        GTGATTGCTC GTGCAATAAA ATCCGGCCTA CAAATCCGAC TAATTGAGAT  
3' C5        ---------- ---------- ---------- ---------- ----------  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     310        320        330        340        350         
PGT 4        CCAGTTTCCT TGGCAAGAAG CAGGAATACC TGAAGGTTGT GAGAATTGTG  
5' C5        CCAGTTTCCT TGGCAAGAAG CAGGAATACC TGAAGGTTGT GAGAATTGTG  
3' C5        ---------- ---------- ---------- ---------- ----------  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     360        370        380        390        400         
PGT 4        ACTTGCTTCC TACAACAGAC TTTGCAAGGT TCATGAAGTC GCTTCACATG  
5' C5        ACTTGCTTCC TACAACAGAC TTTGCAAGGT TCATGAAGTC GCTTCACATG  
3' C5        ---------- ---------- ---------- ---------- ----------  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     410        420        430        440        450         
PGT 4        CTTCAACAGC CTTTTGAAAA TTTGTTCAAA GAGAAAACTC TTAAGCCCTG  
5' C5        CTTCAACAGC CTTTTGAAAA TTTGTTCAAA GAGAAAACTC TTAAGCCCTG  
3' C5        ---------- ---------- ---------- ---------- ----------  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     460        470        480        490        500         
PGT 4        CTGCATAATC TCTGACATGT GTTTTCCTTG GACGG-TGGA TACAGCTGCC  
5' C5        CTGCATAATC TCTGACATGT GTTTTCCTTG GACGG-TGGA TACAGCTGCC  
3' C5        ---------- --TGGTGT-- -TTTTCCTTG AACSGATGAA TACAG-TGCA  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     510        520        530        540        550         
PGT 4        AAGTTCAATG TTCCAAGGAT TATTTTCCAT GGATTTTCTT GCTTCTGTCT  
5' C5        AAGTTCAATG TTCCAAGGAT TATTTTCCAT GGATTTTCTT GCTTCTGTCT  
3' C5        G---TCAATG TACAGA---- --TATTTCAT GAATTT---- -CTGCTCGTT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     560        570        580        590        600         
PGT 4        CTTCTGTCAT CACCTCTTGG GTGTTTCAAA GGTTCACGAG AATGTTACTT  
5' C5        CTTCTGTCAT CACCTCTTGG GTGTTTCAAA GGTTCACGAG AATGTTACTT  
3' C5        CTCTCGTCAT CACT--CTGG GTGTTCAAG- ---TCACGAG AATGT-ACTT  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     610        620        630        640        650         
PGT 4        CTGATTCAGA GTACTTTAAT ATACCTGGAT TGCCTGATCA CATTCAATTT  
5' C5        CTGATTCAGA GTACTTTAAT ATACCTGGAT TGCCTGATCA CATTCAATTT  
3' C5        CGA--TCAGA GTACTT-AAT ATAC-TGGAT --GCTGATCA CAT-CAATTT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     660        670        680        690        700         
PGT 4        ACTAAAGTTC AATTACTAAT ATCCAAGCGG GATGATGACC GTAAAGAGCT  
5' C5        ACTAAAGTTC AATTACTAAT ATCCAAGCGG GATGATGACC GTAAAGAGCT  
3' C5        ACTAAAGTCA A--TACTAAT ATC-AAGCGG -ATGATGAC- GTAAAGAGCT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     710        720        730        740        750         
PGT 4        TCGAGAGCAA ATTTTGGCGG CCGATAAGAA AACATACGGC GCGATTATAA  
5' C5        TCGAGAGCAA ATTTTGGCGG CCGATAAGAA AACATACGGC GCGATTATAA  
3' C5        -CGAGAGCAA ATTT-GGCGG CCGATAAGAA AACATACGGC GCGATTATAA  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     760        770        780        790        800         
PGT 4        ATACCTTCGA AGAGCTAGAG TCGCCATTTA TTGAAAACTA CAAAAAAGCC  
5' C5        ATACCTTCGA AGAGCTAGAG TCGCCATTTA TTGAAAACTA CAAAAAAGCC  
3' C5        ATAC-TTCGA AGAGCTAGAG TCGCCATTTA TTGAAAACTA CAAAAAAGCC  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     810        820        830        840        850         
PGT 4        AAACAAGGAA AAGTTTGGCG CATCGGCCCT GCTTCGCTGT GCAACAAAGA  
5' C5        AAACAAGGAA AAGTTTGGCG CATCGGCCCT GCTTCGCTGT GCAACAAAGA  
3' C5        AAACAAGGAA AAGTTTGGCG CATCGGCC-T GCTTCGCTGT GCAACAAAGA  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     860        870        880        890        900         
PGT 4        GCCCATAGAC AAGGCAGAGA GAGGTAGAAC AGCATCAATT GATGTTCCTG  
5' C5        GCCCATAGAC AAGGCAGAGA GAGGTAGAAC AGCATCAATT GATGTTCCTG  
3' C5        GCCCATAGAC AAGGCAGAGA GAGGTAGAAC AGCATCAATT GATGTTC-TG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     910        920        930        940        950         
PGT 4        AATGCTTAAC ATGGCTTGAT TCACAGCAGC CAAGCTCAGT AGTCTATGTT  
5' C5        AATGCTTAAC ATGGCTTGAT TCACAGCAGC CAAGCTCAGT AGTCTATGTT  
3' C5        AATGCTTAAC ATGGCTTGAT TCACAGCAGC CAAGCTCAGT AGTCTATGTT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     960        970        980        990        1000        
PGT 4        TGTCTTGGAA GCATCTGTAA CTTGCCATCT TCACAACTTA TAGAGCTCGG  
5' C5        TGTCTTGGAA GCATCTGTAA CTTGCCATCT TCACAACTTA TAGAGCTCGG  
3' C5        TGTCTTGGAA GCATCTGTAA CTTGCCATCT TCACAACTTA TAGAGCTCGG  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1010       1020       1030       1040       1050        
PGT 4        TTTAGGCCTT GAAGCATCTA ACAAACCGTT TGTTTGGGTT ATCAGGGGAG  
5' C5        TTTAG-CCTT GAAGCATCTA ACAA-CCGTT TGTT-GGGTT ATCAGGG-AG  
3' C5        TTTAGGCCTT GAAGCATCTA ACAAACCGTT TGTTTGGGTT ATCAGGGGAG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1060       1070       1080       1090       1100        
PGT 4        TGAGTAAATT AGAAGCATTA GAGAAGTGGC TTGTACAAGA AAATTTTGAA  
5' C5        TGAGTAA-TT AGA-GCATTA GAGAAGTGGC TTGTACAAGA AAATTTTGAA  
3' C5        TGAGTAAATT AGAAGCATTA GAGAAGTGGC TTGTACAAGA AAATTTTGAA  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1110       1120       1130       1140       1150        
PGT 4        GAAAGGATTA AAGGAAGAGG CCTTTTGATT CGGGGTTGGG CACCACAAGT  
5' C5        GAT--GATT- ----AAGAGA GCTTTTGGAT CG----CTGG CAC-ACAAGT  
3' C5        GAAAGGATTA AAGGAAGAGG CCTTTTGATT CGGGGTTGGG CACCACAAGT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1160       1170       1180       1190       1200        
PGT 4        ATTGATATTA TCACACCCTG CAGTCGGAGG GTTCTTAACG CATTGCGGCT  
5' C5        AT-GATATTA TCACACC-TG CAGTCGAAG- ----TCTACG CAT-GCG--C  
3' C5        ATTGATATTA TCACACCCTG CAGTCGGAGG GTTCTTAACG CATTGCGGCT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1210       1220       1230       1240       1250        
PGT 4        GGAATTCATC TCT-GGAAGG GATAT--CAG CTGGGGTTCA AATGCTTACA  
5' C5        TGTATTCATC TCTTGGAAAG GATAWTCCAG CCTGGGGGG- ----------  
3' C5        GGAATTCATC TCT-GGAAGG GATAT--CAG CTGGGGTTCA AATGCTTACA  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1260       1270       1280       1290       1300        
PGT 4        TGGCCACTCT TTGCAGACCA ATTTTGCAAT GAGAAGTTGA TTGTGAATGT  
5' C5        ---------- ---------- ---------- ---------- ----------  
3' C5        TGGCCACTCT TTGCAGACCA ATTTTGCAAT GAGAAGTTGA TTGTGAATGT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1310       1320       1330       1340       1350        
PGT 4        TTTAAGGATT GGTGTGAGTG TTGGAGTGGA AGTTCCAATG AATTTTGGAG  
5' C5        ---------- ---------- ---------- ---------- ----------  
3' C5        TTTAAGGATT GGTGTGAGTG TTGGAGTGGA AGTTCCAATG AATTTTGGAG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1360       1370       1380       1390       1400        
PGT 4        AAGAAGAGAA GATTGGAGTA TTGGTGAATA AGGAAAATGT CAAAACGGCT  
5' C5        ---------- ---------- ---------- ---------- ----------  
3' C5        AAGAAGAGAA GATTGGAGTA TTGGTGAATA AGGAAAATGT CAAAACGGCT  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1410       1420       1430       1440       1450        
PGT 4        ATAAACATAC TGATGGATGA TGGAGAGGAA AGAAATGCGA GAAGAAGTGC  
5' C5        ---------- ---------- ---------- ---------- ----------  
3' C5        ATAAACATAC TGATGGATGA TGGAGAGGAA AGAAATGCGA GAAGAAGTGC  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1460       1470       1480       1490       1500        
PGT 4        CAGAGAGTTT GGAGAGTTGG CTAAAAGAGC TATAGATGAA GGTGGATCTT  
5' C5        ---------- ---------- ---------- ---------- ----------  
3' C5        CAGAGAGTTT GGAGAGTTGG CTAAAAGAGC TATAGATGAA GGTGGATCTT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1510       1520       1530       1540       1550        
PGT 4        CCTATAACAA CGTCGAATTA TTTATGCAAG ATATCATGCA ACAGCCGAGC  
5' C5        ---------- ---------- ---------- ---------- ----------  
3' C5        CCTATAACAA CGTCGAATTA TTTATGCAAG ATATCATGCA ACAGCCGAGC  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     1560       1570       1580       1590       1600        
PGT 4        TCAGAAGTGA TTTAA----- ---------- ---------- ----------  
5' C5        ---------- ---------- ---------- ---------- ----------  
3' C5        TCAGAAGTGA TTGGCGGCCG CCAGCTTGGG CCCGAACAAA AACTCATCTC  
 
Figure 23. Sequencing Results Confirming Insertion of PGT 4 into the pPICZ A vector 
 
Frame shifting PGT 4 in pPICZ A 
 Upon alignment of the PGT 4 sequencing results, it was found that the c-myc epitope and 
histidine tags on the 5’ end of the pPICZ A vector, immediately following the PGT 4 sequence, 
were out-of-frame.  These tags are essential for identification and purification of the enzyme. 
Without these tags in frame, the presence of PGT 4 would not be visible on a Western blot. Thus, 
the frame shift was studied. It was found that only one base pair needed to be added to the 3’ 
primer to successfully frame shift the sequence. The challenge arose because the 3’ primer base 
pair length was not a multiple of three. This fact led to a frame shift of the tags which were 
designed with specific amino acid codon sequences which are in multiples of three.  See Figure 7 
for more details.  
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 A new 3’ end primer, CSP 164R was designed inserting one guanine base pair to the 
primer sequence. A new 5’ end primer, CSP 163F, was designed to more closely match the 
melting temperature of the new primer sequence to ensure proper annealing and amplification by 
PCR.  Amplification by PCR resulted in a desired band of around 1500 bp (Figure 24). PCR 
product was rapidly cloned into the pCR
®
 4-TOPO
® 
vector, digested with KpnI and NotI, and 
ligated into pPICZ A vector also digested with KpnI and NotI.  
  
 
Figure 24. Digestion of pPICZ A vector and PGT 4 in pCR
®
 4-TOPO
®
. M is 1 kb ladder. 
Lanes 1-2 are pPICZ A vector digested with KpnI and NotI.  Lanes 3-4 are PGT 4 in pCR
®
 4-
TOPO
®  
digested with KpnI and NotI. Bands from Lanes 1-2 and bands at 1500 bp from Lanes 3-
4 were excised, gel purified, and used for ligation.  
 
 The ligation product was transformed into OneShot
® 
Top 10 Cells. Colonies were grown 
on selective LB plates with zeocin (25 mg/L).  Several transformant colonies grew overnight on 
the plates at 37
o
C.  Seventeen colonies were chosen at random for PCR screening. A PCR 
screening was conducted with CSP 163F and CSP 164R to verify the presence of the PGT 4 
within the pPICZ A vector. Colonies 5 and 13 showed a very light positive band at around 1500 
bp, suggesting PGT 4 was successfully ligated in the pPICZ A vector (Figure 25).  
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Figure 25. PCR Screening of Transformed ligated pPICZ A and PGT 4.  M is 1 kb ladder. 
Lanes 1-13 are PCR product from respective colonies. Lane 19 is a positive control. Colonies 5 
and 13 showed faint bands at 1500 bp suggesting presence of PGT 4 within plasmid DNA.  
 
 The colonies containing full length PGT 4, Colonies 5 and 13, were inoculated into LB 
media with zeocin (25 mg/L). DNA plasmid was isolated and sent for sequencing. The 
sequencing results confirmed the insertion of PGT 4 into the pPICZ A vector with the c-myc 
epitope and histidine tags in frame (Figure 26).  
 
 
 
 
Figure 26. Frameshift of pPICZ A tags for identification and purification. PGT 4 
sequencing results of Colonies 5 and 13 showed tags in frame allowing for identification and 
purification when transformed into yeast (Invitrogen).  
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Transformation of PGT 4 into Pichia pastoris 
 X-33 strain yeast cells were grown in YPD media and harvested for electroporation. 
pPICZ A vector storing the PGT 4 sequence was linearized with BstXI for electroporation. The 
Invitrogen manual suggests the use of SacI, BstXI, and PmeI.  A restriction map of the PGT 4 
sequence revealing an internal cutting site of SacI. Thus, BstXI or PmeI had to be used. BstXI 
was chosen due to its availability in lab stocks. Isolation of plasmid was conducted via MidiPrep, 
and DNA was digested overnight with BstXI. To confirm complete linearization, a 2 μL sample 
from the digestion was run on an agarose gel. The results confirmed the complete digestion. 
(Figure 27).  
   
Figure 27. Linearization of PGT 4 in pPICZ A with BstXI. M is 1 kb ladder. Lane 1 is PGT 4 
in pPICZA DNA plasmid. Lane 2 is sample from overnight digestion of PGT 4 in pPICZ A with 
BstXI.  Absence of lines in lane confirms complete digestion of DNA ready for concentration.  
 
 The digested DNA was concentrated by the processes of phenol: chloroform extraction 
and ethanol precipitation. The DNA was resuspended in 20 μL distilled water for 
electroporation. Electroporation with concentrated DNA and yeast cells was conducted as 
described and sampled were spread on selective YPDS plates (zeocin 100 mg/L). After 
incubation for three days, six colonies were found and PCR screened with CSP 163F and CSP 
164R to verify the presence of the PGT 4 within the yeast genome (Figure 28).  
 M  1  2  3  4   5   6  7  8   9   
10000 
8000 
6000 
4000 
2000 
1500 
1000 
900 
800 
700 
600 
    500      
 
69 
 
   
 
Figure 28. PCR Screening of Transformants of Electroporation I. M is 1 kb ladder. Lanes 1-
6 are PCR product from respective colonies with CSP 163F and CSP 164R.  Lane 7 is positive 
control. Lack of bands suggests absence of PGT 4 in yeast genome of Colonies 1-6.  
 
 When the presence of PGT 4 was not found, it was hypothesized that the yeast cells were 
not properly lysed when isolating DNA for PCR amplification. Presence of the colonies on the 
selective plate indicated that the colonies should contain the pPICZ A vector sequence with 
zeocin resistance. Cell lysing and PCR screens were repeated several times with identical results. 
A second electroporation with new linearized DNA and yeast cells was conducted. PCR 
screening of nine transformed colonies still found no presence of PGT 4 in the yeast genome 
(Figure 29).  
   
 
Figure 29. PCR Screening of Transformants of Electroporation II. M is 1 kb ladder. Lanes 
1-10 are PCR product of respective colonies with AOX1 primers. Lane 11 is a positive control. 
Lane 12 is a negative control. Lack of bands suggests absence of PGT 4 in yeast genome of 
Colonies 1-10.  
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 Possible solutions to optimize transformation success were studied. The Invitrogen 
manual recommends electroporation with 1µg/µL and to use 5-10 µL.  In previous 
electroporations, the recommended amount of DNA was used but not within the recommended 
volume due to insufficient drying after ethanol precipitation. To increase concentration of 
linearized DNA, a Speed Vac Concentrator (Thermo Electron Corporation) for fifteen minutes. 
This process allowed all remaining ethanol to be evaporated and the DNA pellet was 
resuspended in 5 µL.  
 A third electroporation was conducted preparing the linearized DNA as described. The 
transformation product was plates on selective YPDS plates (zeocin 100mg/L). After incubation 
at 28
o
C for three days, eleven colonies were found and screened by PCR for the presence of PGT 
4.  Three colonies showed PCR product just above 1500 bp. These bands were the desired length 
representing the 1467 bp PGT 4 sequence and the 300 bp AOX1 priming site sequence (Figure 
30).  
   
 
Figure 30. PCR Screening of Transformants of Electroporation III. M is 1 kb ladder. Lanes 
1-11 are PCR product of respective colonies with AOX1 primers. Lane 12 is a positive control. 
Lane 13 is a negative control. Bands around 1500 bp suggest presence of PGT 4 in yeast genome 
of Colonies 7-9.  
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 These bands confirmed the sequence of PGT 4 within the yeast genome in Colonies 7, 8, 
and 9.  These yeast colonies were restreaked on fresh YPD plates, grown at 28
o
C for 2 days, and 
saved at 4
o
C.  
Western Blot Analysis of Test Inductions 
 Test inductions of Colonies 7, 8, and 9 were conducted. Samples were taken at 
0,6,12,24,36,48,60,72,84, and 96 hours. Cell pellets were saved at -80
o
C for SDS-PAGE and 
Western Blot analysis.  
 Samples were lysed and resuspended in Breaking Buffer (Appendix A). Protein aliquots 
from all samples were used for SDS-PAGE, electro-blotted onto a nitrocellulose membrane, and 
shaken with appropriate antibodies for Western blot analysis. Development of the Western blot 
showed protein production was optimum at 6-12 hours post-induction. Figure 31 shows the 
Western blots of all test induction samples of each colony.  
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Figure 31. Western Blot Analysis of Test Inductions. A. Bands were found around 54 kD, the 
hypothesized protein size of PGT 4. The heaviest bands occur at 6 and 12 hours suggesting 
optimum protein production post-induction. B. Lighter bands found at later times post-induction. 
Results suggest longer incubation time decreases protein production.  
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 On the two Western blots, bands were found around 54 kD, the hypothesized protein size 
of PGT 4. The darkest bands occurred at 6 and 12 hours suggesting optimum protein production 
post-induction. Much lighter bands were found at later times post-induction. These results 
suggest a longer incubation time decreases protein production.  
 
Purification of PGT 4  
 To test for specific protein function, PGT 4 was isolated from all other proteins produced 
within yeast. The C-terminal His-tag within the pPICZ A vector allowed PGT 4 to be purified 
using metal affinity chromatography for purification. Yeast cells were grown to optimum post-
induction time of 12 hours and harvested. The cell pellet was resuspended in Breaking Buffer 
with βME to prevent the formation of disulfide bridges and PMSF to prevent protease activity in 
the protein. The cells were lysed by French press, and the cell lysate was centrifuged. The 
supernatant was desalted with a PD-10 column to remove any salt that could interfere with 
binding to the metal affinity column. The desalted elution was subsequently applied to an IMAC 
column, and fractions were saved at 4
o
C to be analyzed by SDS-PAGE, Silver Staining, and 
Western blot. The Silver Staining shows three dark lanes which are the washes from the IMAC 
column eluting protein without a His tag. The next four lanes show the elutions of tagged PGT 4 
which were concentrated for enzyme assay. The product of the concentration, the purified 
enzyme, is shown in the last lane (Figure 32). The Western Blot shows the lack of tagged 
enzyme in the washes, the tagged enzyme in the elutions, and the final purified enzyme used for 
assay (Figure 33). The final concentration of purified enzyme used for assay was 0.91 mg/mL.  
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Figure 32. Silver Stain of IMAC Purification for PGT 4 Screening. M represents low range 
protein ladder. W1-3 represent wash fractions collected from IMAC column. The bands 
represent all proteins washed away to purify PGT 4. E1-4 signify elutions from IMAC after 
addition of imidazole. These four fractions were concentrated for protein analysis. PE represents 
purified PGT 4 used for enzyme screening.  
 
 
 
Figure 33. Western Blot of IMAC Purification for PGT 4 Screening. M represents low range 
protein ladder. W1-3 represent wash fractions collected from IMAC column. The bands 
represent all proteins washed away to purify PGT 4. E1-4 signify elutions from IMAC after 
addition of imidazole. These four fractions were concentrated for protein analysis. PE represents 
purified PGT 4 used for enzyme screening.  
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Screening of PGT 4 for Flavonoid Glucosyltransferase Activity 
 A total of 14 flavonoids were used as potential acceptor substrates to screen for GT 
activity with PGT 4. Each test reaction was performed in duplicate with each flavonoid substrate. 
A negative control using enzyme denatured with HCl were also performed in duplicate with each 
flavonoid substrate. This negative control served as a background reading of activity with each 
substrate. The test results were corrected against these background readings to verify positive 
activity. A second negative control was conducted using denatured PGT 4 that had been boiled 
for ten minutes with quercetin. A positive control using young grapefruit leaf extract as the GT 
enzyme source was performed with quercetin. A second positive control combining young 
grapefruit leaf extract and PGT 4 was performed to test for inhibiting effects of glucose 
incorporation. The amount of radiolabeled 
14
C-UDP-glucose transferred to flavonoid substrates 
was analyzed using a Beckman LS 6500 scintillation counter to determine cpm in 250 µL. 
Results show the average cpm incorporation of the substrates tested with PGT 4 (Table 10).  
Table 10. Screening of PGT 4 for Flavonoid Glucosyltransferase Activity 
 (Note: 20000 cpm 
14
C-UDP-glucose was used per reaction) 
 Substrate Name Substrate Structure 
Average cpm 
incorporation 
(n=2, 250 µL 
ethyl acetate) 
Flavanones 
Naringenin 
 
n.a. 
Hesperitin 
 
10 
Eriodictyol 
 
n.a. 
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Isosakuranetin 
 
n.a. 
Flavones 
Apigenin 
 
n.a. 
Luteolin 
 
n.a. 
Diosmetin 
 
15 
Scutellerin 
 
n.a. 
Flavonols 
Kaempferol 
 
n.a. 
Quercetin 
 
n.a. 
Fisetin 
 
26 
Gossypetin 
 
 
n.a. 
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4’-
methoxyflavonol 
 
 
 
 
 
n.a. 
 
 
 
Isoflavone 
4’-acetoxy-7-
hydroxy-6-
methoxy-
isoflavone 
 
 
 
 
2 
 
Controls  
Positive  
Young grapefruit leaf extract + Quercetin 914 
Young grapefruit leaf extract + PGT 4 + 
Quercetin 
1645 
Negative  Denatured PGT 4 + Quercetin  73 
 
 According to these results, no significant GT activity was found with PGT 4. All tests 
were conducted in duplicate, and the results were corrected against duplicate background 
controls and for 250 μL ethyl acetate. The positive control with crude extract showed activity as 
several GTs are found within young grapefruit leaf tissue. The second positive control, using 
crude extract and purified enzyme, showed increased activity levels compared to the crude 
extract. This result could suggest that PGT 4’s preferred substrate acceptor is found within the 
crude extract. Also, this finding could be explained by PGT 4 being a part of a multi-enzyme 
complex. The increased activity of the control could be a result of PGT 4’s interaction with other 
necessary enzymes to exhibit glucosyltransferase activity.  
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SUMMARY and FUTURE WORK 
 PGT 4 was successfully reconstructed to its full-length of 1467 base pairs. The c-myc 
epitope and histidine tags were shifted into frame allowing for identification and purification of 
PGT 4 for flavonoid GT analysis. PGT 4 was found to have predicted size of around 54 kD. 
Optimum post-induction time was determined to be 12 hours by Western blot analysis.  SDS-
PAGE, Silver staining, and Western blot analysis were conducted to ensure presence of purified 
protein.  PGT 4 was screened against 14 flavonoid substrates for flavonoid glucosyltransferase 
activity. No significant GT activity was found with PGT 4. Repeats of the screening with these 
flavonoids and the controls could be done to ensure accurate results. If the results of the positive 
controls are duplicated, the possible implications could be explored. A compound profile could 
be created to narrow down potential substrate acceptors of PGT 4.  
 Further screening with representatives from other flavonoid subclasseses not previously 
tested could be conducted to find PGT 4’s preferred substrate acceptor. Although PGT 4 did not 
exhibit any flavonoid glucosyltransferase activity with tested flavonoids, the enzyme could be 
further tested to reveal activity with other secondary metabolites such as simple phenolic 
compounds. Previous work has shown GT activity with some phenolic compounds using reverse 
high performance liquid chromatography (Wamucho 2012, Hayford 2012).  
 If no glucosyltransferase activity is found, it may be necessary to use a yeast expression 
vector that can cleave the fusion tag after purification to rule out any interference of the extra 
sequence on the GT activity of the enzyme.  
 This work has helped to narrow down the list of possible substrate acceptors of PGT 4. 
With this knowledge, further work, including the suggested methods, will elucidate the preferred 
substrate of PGT 4 and help to distinguish its role in grapefruit metabolism.   
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Buffer Recipes 
 
50X TAE Buffer 
• 50 mL EDTA (pH 8.0) 
• 28.6 mL glacial acetic acid 
• 121 grams Tris Base 
• Add dH2O to 1000 mL 
• Add 20 mL of 50X TAE to 980 mL dH2O to dilute to 1X TAE for agarose gels  
 
1 M Potassium Phosphate Buffer, pH 6 
 
• 132 mL 1 M K2HPO4  
• 868 mL 1 M KH2PO4 
• Adjust pH to 6 with KOH if needed.  
• Autoclave for 20 minutes and store at room temp 
 
Breaking Buffer , pH 7.4 
 
• 6 grams monobasic sodium phosphate 
• 372 mg EDTA 
• 50 mL glycerol 
• Dilute to 900 mL 
• Adjust pH to 7.4 with NaOH 
• Dilute to 1 Liter  
• Store at 4oC 
• Add desired protease inhibitors 
o 50 µL of 0.1 M PMSF was added to 5 mL BB before lysing cell pellets.  
 
5X SDS-PAGE TANK Buffer 
 
• 15.1 grams Tris base  
• 94 grams glycine 
• Dilute to 900 mL with distilled water 
• Add 50 mL 10% SDS  
• Dilute to 1 Liter with distilled water 
 
 
 
 
 
 
10X Western Blot Transfer Buffer 
 
 
89 
 
• 30.3 grams Tris base 
• 144.1 grams glycine 
• Dilute to 1 Liter 
• Store at 4oC 
• 100 mL 10X stock 
• 700 mL distilled water 
• 200 mL methanol 
 
5X Tris-Buffered Saline (TBS) 
 
• 40 grams NaCl 
• 1 gram KCl 
• 15 grams Tris base 
• Dilute to 800 mL with distilled water 
• Adjust pH to 7.4 with HCl 
• Dilute to 1 Liter with distilled water 
 
Alkaline phosphatase buffer 
 
• 1.17 grams NaCl 
• 203 mg MgCl2 – H2O 
• 2.42 grams Tris 
• Dilute to 80 mL with distilled water 
• Adjust pH to 9.5 with HCl 
• Dilute to 200 mL with distilled water 
 
Blocking Solution 
 
• 2.5 grams milk powder 
• 40 µL sodium azide 
• Dilute to 50 mL with 1X TBS 
 
Developing Solution  
 
• 45 mL alkaline phosphatase buffer 
• Add following immediately before developing Western blots 
• 180 µL NBT in 0.083 g/mL in 70% N,N-dimethylformamide 
• 180 µL BCPIP in 0.42 g/mL in 100% N,N-dimethylformamide 
 
 
 
 
 
50 mM Phosphate Buffer (pH 7.5)  
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• 0.2918 grams monosodium phosphate 
• 0.7733 grams disodium phosphate 
• Add 900 mL distilled water 
• Adjust pH to 7.5 
• Dilute to 1 Liter 
 
Column Buffer (pH 7.5) 
 
• 0.2918 grams monosodium phosphate 
• 0.7733 grams disodium phosphate 
• 17.532 grams NaCl 
• Add 900 mL distilled water 
• Adjust pH to 7.5 
• Dilute to 1 Liter 
 
IMAC Elution Buffer (pH 7.5) 
 
• 0.2918 grams monosodium phosphate 
• 0.7733 grams disodium phosphate 
• 17.532 grams NaCl 
• 10.21 grams imidazole 
• Add 900 mL distilled water 
• Adjust pH to 7.5 
• Dilute to 1 Liter 
 
IMAC MES Buffer (pH 5) 
 
• 3.9046 grams 2-(N-morpholine)-methanesulfonic acid (MES) 
• Add 900 mL distilled water 
• Adjust pH to 5 
• Dilute to 1 Liter  
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Media and Stock Solution Recipes 
Low Salt LB Media 
• 10 grams tryptone 
• 5 grams yeast extract 
• 5 grams sodium chloride 
• Add 450 mL dH2O and stir with magnetic stirrer 
• Adjust pH to 7.5 using 6M NaOH 
• Fill up to 500 mL with dH2O 
• Autoclave for 20 minutes 
• Cool to room temperature 
• Store at 4 oC  
• Add antibiotic as necessary  
o Ampicillin – 100mg/L 
o Zeocin -25mg/L 
 
 
LB Agar Plates 
 
• Low Salt LB media 
• Agar ( 15 grams/L) 
• Add agar to desired amount of Low Salt LB media and autoclave for 20 minutes 
• Cool at 42oC 
• Add desired antibiotic (see above concentrations) 
• Pour into sterile plates 
• Allow to harden and cool.  
• Store inverted at 4oC  
• Cover LB Zeocin plates with aluminum foil  
 
Phenol:Chloroform Solvent 
 
• Combine equal parts of phenol and 0.5 M Tris-HCl, pH 8 
• Add 0.1% 8-hydroxyquinoline 2-carboxylic acid 
• Stir mixture for 15 minutes.  
• Remove upper layer of the mixture 
• Add an equal volume of 0.1 M Tris-HCl to the mixture 
• Stir for 15 minutes 
• Repeat above steps until pH of phenol: chloroform is above 7.8  
 
 
 
 
10 X YNB (pH 5.4)  
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• 134 grams of yeast nitrogen base (YNB) 
• 100 grams ammonium sulfate 
• Add 900 mL distilled water 
• Adjust pH to 5.4 
•  Dilute to 1000 mL with distilled water 
• Heat solution to dissolve completely  
• Filter sterilize and store solution at 4oC 
 
500 X B (0.02% Biotin) 
 
• 20 milligrams biotin  
• Dilute to 100 mL with distilled water 
• Filter sterilize and store solution at 4oC 
 
10 X D (20% Dextrose) 
 
• 200 grams of D-glucose 
• Dilute to 1000 mL distilled water 
• Filter sterilize and store at room temp 
 
10 X M (5% Methanol) 
 
• 5 mL methanol 
• Add 95 mL distilled water 
• Filter sterilize and store at 4oC 
 
10 X GY (10% Glycerol) 
 
• 100 mL glycerol 
• Dilute to 1000 mL with distilled water 
• Filter sterilize and store at room temperature 
 
 
YPD Liquid Media 
 
• 10 grams yeast extract 
• 20 grams peptone 
• Dilute to 900 mL with distilled water 
• Adjust pH to 7.5 using 6M NaOH 
• Autoclave for 20 minutes 
• Add 100 mL 10 X D 
 
 
YPD Agar Plates 
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• Desired amount of liquid YPD media  
• Add 15 grams agar/ liter 
• Autoclave for twenty minutes 
• Add antibiotic, Zeocin (100 mg/L) 
• Store in dark at 4oC 
 
YPDS Media and Plates 
 
• 10 grams yeast extract 
• 20 grams peptone 
• 182 grams sorbitol 
• Dilute to 900 mL distilled water 
• Adjust pH to 7.5 using 6M NaOH 
• For plates, 15 grams agar / liter 
• Autoclave for 20 minutes 
• Add 100 mL 10 X D 
• Cool solution to 42oC in water bath 
• Add antibiotic, Zeocin (100 mg/L) 
• Store plates in dark at 4oC 
 
BMGY / BMMY Media 
 
• 10 grams yeast extract 
• 20 grams peptone 
• Dilute to 700 mL with distilled water 
• Adjust pH to 7.5 using 6M NaOH 
• Autoclave for 20 minutes 
• Cool to room temp and add: 
- 100 mL sterile 1M potassium phosphate buffer, pH 6 
- 100 mL sterile 10 X YNB 
- 2 mL sterile 500 X B 
- 100 mL sterile 10 X GY for BMGY 
- 100 mL sterile 10 X M for BMMY 
• Store at 4oC 
 
2X PCR Master Mix 
 
• 200 µL 5X GoTaq Reaction Buffer 
• 2 µL 100 mM dNTP Mix 
• 5 µL GoTaq enzyme of 5 u/ µL stock 
• Add sterile, distilled water to 500 µL 
 
Coomassie Blue staining solution 
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• 6 mg Coomassie Brilliant Blue G250 
• 10 mL acetic acid 
• 40 mL methanol 
• Dilute to 100 mL with distilled water 
 
Destaining solution 
 
• 300 mL 30% methanol 
• 100 mL 10% acetic acid 
• Dilute to 1 L with distilled water 
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APPENDIX C 
Gel Recipes 
0.8% Agarose Gel  
• 0.24 grams of agarose 
• Add 30 mL 1X TAE (pH 8.2) 
• Heat for 1 minute in microwave 
• Add dH2O to fill back up to 30 mL 
• Add 2.5 μL of EtBr (10mg/mL) 
 
SDS-PAGE 
 
 10 % Separating Gel 5 % Stacking Gel 
Distilled water 2.3 mL 1.5 mL 
40%  Acrylamide and  
bis-acrylamide solution, (19:1) 
1.3 mL 260 μL 
1.5 M Tris, pH 8.8 1.3 mL -------- 
1.0M Tris, pH 6.8 -------- 250 μL 
10% SDS 50 μL 20 μL 
TEMED* 2 μL 2 μL 
10% APS 50 μL 20 μL 
  * add last                       Total 5 mL 2 mL 
 
 
